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In contemporary clinical practice, percutaneous coronary intervention (PCI) is one of the most common 
methods to treat ischemic heart disease. It has proven to be very effective in appropriately selected 
patients. However, clinical discretion among interventional clinicians in the absence of definitive 
evidence-based guidelines results in significant variation in clinical practice of PCI. The objective of this 
dissertation research is to study the effect of such variation in three aspects on patient outcomes following 
PCI: (i) post-discharge statin prescription versus no prescription in the setting of otherwise aggressive 
medical therapy; (ii) use of multiple stents versus a single stent when either approach is clinically 
feasible; (iii) use versus no use of stent postdilation.  
Patients were evaluated from multiple data sources.  The first source included the multi-center 
National Heart, Lung, and Blood Institute (NHLBI) Dynamic registry recruitment Wave 4 (2004) and 
Wave 5 (2006).   For Aim 1 (post-discharge statin vs. no post-discharge statin), patient eligibility criteria 
included receipt of aspirin, thienopyridines and at least one type of cardiovascular protective medication 
(angiotensin-converting enzyme inhibitors, Beta blockers, or Calcium channel blockers) after the PCI 
procedure, and no in-hospital death.  Risk of adverse events was compared between post-discharge statin 
recipients and non-recipients at one-year follow up. Results showed that post-discharge statin use was 
associated with a reduced risk of mortality and the composite endpoint of death/MI, death/MI/CABG.  
These data support the routine use of post-PCI statin therapy in the presence of otherwise aggressive 
medical therapy. 
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For Aim 2 (multiple versus single stents), the DEScover Registry, a prospective, multicenter, 
observational study among 140 clinical centers in the United States, was used. The eligibility criteria for 
this analysis included: receipt of at least one stent for a lesion treated with PCI and the following 
characteristics: lesion not previously treated; lesion length of 10 to 32mm (i.e. able to be treated with 
either a single or multiple stents); and an angiographically successful procedure. Survival analysis over 1-
year post-PCI showed that patients who received multiple stents had a similar risk of adverse events 
compared to patients who received a single long stent for each lesion treated.  Thus, this analysis was 
unable to provide definitive evidence for a preference of single versus multiple stents for lesions in the 
range of 10 to 32 mm. 
For Aim 3 (postdilation versus no postdilation), the Dynamic registry recruitment Wave 4 (2004) 
and Wave 5 (2006) were used. Patient eligibility criteria for this analysis included receipt of >1 stent and 
an angiographically successful PCI procedure. Survival analysis over 1-year post-PCI showed that among 
PCI patients who presented with acute MI, postdilation appears to significantly increase the risk of death 
by as much as 3-fold.  However, because this finding was observed only among patents with one lesion 
treated but not among patients with multiple lesions treated, the possibility of a chance finding exists.  
Moreover, among PCI patients who had no acute MI, lesion postdilation did not appear to be associated 
with either a benefit or increased risk of adverse cardiac events.  Thus, this analysis indicated no obvious 
clinical benefit associated with postdilation in the setting of PCI patients who had no acute MI, and a 
potential hazardous effect in the setting of acute MI. 
Our study has significant public health importance. Heart disease is the leading cause of mortality 
in nearly every region of the world, accounting for an estimated 30% of all deaths. Coronary heart disease 
(CHD) is the principal type of heart disease. The public health significance of our study is that 
investigating the effect of variation in clinical PCI practice can be a benefit to numerous CHD patients all 
over the world.   
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1.0  DISSERTATION OVERVIEW AND OBJECTIVE 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Coronary artery 
disease (CAD) is the principal type of heart disease, and nearly half of all cardiovascular deaths are 
attributed to CAD worldwide.  In 2002 in the United States, approximately 71% of heart disease deaths 
were attributed to CAD.  Thus, the prevention and optimal treatment of obstructive CAD represents a 
major public health imperative. 
Percutaneous coronary intervention (PCI) is one of the most common treatments for CAD in 
contemporary clinical practice. Detailed guidelines that cover a variety of clinical circumstances in which 
PCI is performed have been published by the respective professional organizations including the 
American College of Cardiology (ACC), American Heart Association (AHA), and the Society for 
Cardiovascular Angiography and Interventions (SCAI). However, as with many surgical procedures, 
individual operator discretion continues to play a considerable role in the choice of patients deemed 
suitable for PCI, and how these patients will ultimately be treated with contemporary stent technology and 
adjunctive pharmacological therapy. Thus, there is significant variation in clinical practice of PCI today, a 
condition unlikely to change in the near future and one that warrants continuous appraisal and evaluation.  
Therefore, the purpose of this dissertation is to evaluate the effect of three different variations in 
how PCI is being performed in relation to important peri-procedural and post-discharge patient outcomes.  
Specifically, the following questions are addressed in a series of three research papers: 
1.   Among patients who undergo successful PCI procedures and receive: (i) aspirin; (ii) 
thienopyridines; and (iii) one or more cardiovascular protective medications (ACE inhibitors, beta 
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blockers, or calcium channel blockers), does the addition of post-discharge statin therapy provide 
additional clinical benefit? 
2.   What is the effect on patient outcome of the use of single versus multiple stents for 
atherosclerotic lesions that are of length 10-32 mm and, theoretically, based on lesion length and available 
stent sizes, can these lesions be treated with a single stent?   
3. After initial PCI dilation of one or more obstructive lesions, does stent post-dilation (i.e. 
for presumed optimal stent expansion) significantly affect patient outcomes?  In addition, does the effect 
of this procedural approach vary among patients who present with acute myocardial infarction (MI) 
versus those presenting without acute MI?  
The first and third investigations were conducted among PCI patients enrolled and followed in the 
National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry of PCI.  The second investigation 
was conducted among PCI patients enrolled and followed in the Cordis-funded DEScover registry.  As 
described in this dissertation, both of these databases include consecutively enrolled PCI patients in “real-
world” clinical practice across a variety of clinical centers throughout North America. 
 2 
2.0  BACKGROUND 
Heart disease is the leading cause of morbidity and mortality in the United States. (Rosamond, Flegal et 
al. 2007) Obstructive coronary artery disease (CAD) is a major cause of heart disease, such as myocardial 
infarction (MI) and its associated disability and mortality.  
Technological advances in the treatment of blocked arteries include the introduction of coronary 
artery bypass graft surgery (CABG) in the late 1960s, and percutaneous transluminal coronary 
angioplasty (PTCA), also called balloon angioplasty)), introduced in the late 1970s and now often called 
percutaneous coronary intervention (PCI). Both CABG and PCI are preceded by cardiac catheterization, 
which measures the location and extent of coronary artery blockage. The choice of procedure (PCI versus 
CABG) depends on a number of factors such as location, number, and extent of the obstructive lesions. 
In the practice of PCI, coronary artery stenting was introduced in 1996.  A stent is a wire mesh 
tube used to prop open an artery that has recently been cleared using angioplasty. According to the 
American Heart Association (AHA), 70–90 percent of PCI procedures involve the implantation of one or 
more stents.  
The practice of PCI continues to grow.  According to the National Center for Health Statistics, the 
rate of coronary stent insertion procedures for adults age 45 years or older doubled from 1996-97 to 2002-
03 (from 22 per 10,000 to 49 per 10,000).  Moreover, the rate of this procedure tripled for adults ages 75 
years and older during the period 1996-97 to 2002-03 (from 23 per 10,000 to 73 per 10,000). (See Figure 
1.1) 
 3 
Developed during the last 30 years, stenting together with other procedures and medical therapy 
have improved survival after heart attack. It is estimated that around 70 percent of survival improvement 
in heart attack mortality is contributed by these technologies.  
The development of drug eluting stents (DES) has been a milestone in PCI. The rate of restenosis 
and target vessel revascularization, a hallmark limitation (i.e. “Achilles heel”) of treatment with 
conventional bare metal stents, has been dramatically reduced with the use of DES.  This has enabled a 
broader range of patients with more severe lesions deemed suitable and ultimately selected for PCI.  
Detailed guidelines that cover a variety of clinical circumstances in which PCI is performed have been 
published by the respective professional organizations including the American College of Cardiology 
(ACC), American Heart Association (AHA), and the Society for Cardiovascular Angiography and 
Interventions (SCAI) (Smith, Feldman et al. 2006). However, operator discretion continues to play a 
major role in the choice of patients deemed suitable for PCI, and how these patients will ultimately be 
treated with contemporary stent technology (e.g. bare metal stents versus DES) and adjunctive 
pharmacological therapy (e.g. routine use of statin therapy). Thus, as with many surgical procedures, 
there is significant variation in the manner in which PCI is practiced today.  This circumstance is likely to 
remain largely in effect in the near future and hence provides the rationale for continuous appraisal and 
evaluation. 
Despite published guidelines, many variations in PCI practice are not based on evidence-based 
guidelines, and clearly some of this variance in practice is likely to impact patient outcomes.  Thus, it is of 
considerable public health importance to study important variations in the real-world practice of PCI and 
how these variations may impact patient outcomes. 
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 Figure 1-1 Coronary artery stents procedure from 1996 to 2003 
2.1 POST-PROCEDURAL MEDICAL THERAPY 
The increasing number of PCI procedures being peformed each year reflects overall excellent acute 
angiographic results and low rates of restenosis in most patient subgroups.  However, with the 
introduction of DES, in particular, there exists a significant clinical concern -- subacute stent thrombosis 
(SAT).  The occurrence of SAT, which can happen many months or even years after the index PCI, has an 
alarming case-fatality rate of up to 50%.  Thus, considering the increasing number of PCI procedures 
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being performed, particularly with DES, and the more complex vessel lesions being treated, the role of 
antiplatelet/anticoagulant therapy (i.e. to reduce the risk of SAT) has become increasingly more 
important. 
2.1.1 Aspirin 
It is well established that aspirin prevents ischemic events and prolongs survival among cardiovascular 
disease patients. It irreversibly blocks the formation of thromboxane A2, which is a mediator of platelet 
aggregation.  
Theroux et al. conducted a randomized, double-blind, placebo-controlled trial in the 1980s to test 
the effectiveness of aspirin for treating acute unstable angina. (Theroux, Ouimet et al. 1988) A total of 
479 patients with acute unstable angina were randomized to four groups: aspirin (325 mg twice daily), 
intravenous heparin sodium, both, or neither. The incidence of myocardial infarction was significantly 
reduced in the groups receiving aspirin (3% vs. 12%; P = 0.01). A larger study, ISIS-2 (Second 
International Study of Infarct Survival) trial randomized 17,187 patients with onset of suspected acute 
myocardial infarction within 24 hours into four treatment groups: aspirin therapy (160 mg/d), 
streptokinase, both, and neither.(1988) The study patients had ST-segment elevation, ST-segment 
depression, bundle-branch block, or other electrocardiographic abnormalities. Aspirin reduced 5-week 
vascular mortality by 23% when compared to the neither treatment group (9.4% vs. 11.8%, P<0.00001). 
Aspirin also significantly reduced non-fatal reinfarction (1.0% vs. 2.0%) and non-fatal stroke (0.3% vs. 
0.6%), and was not associated with any significant increase in cerebral hemorrhage or in bleeds requiring 
transfusion.  
A very large meta-analysis of 287 randomized trials involving 135,000 patients showed that 
aspirin or other antiplatelet therapy reduced the combined outcome of any serious vascular event by about 
one quarter; non-fatal myocardial infarction was reduced by one third, and vascular mortality by one 
sixth.(Antithrombotic Trialists 2002) The above results firmly support the conclusion that aspirin is 
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protective for occlusive vascular events in patients with an acute myocardial infarction or ischemic stroke, 
unstable or stable angina, previous myocardial infarction, peripheral arterial disease, or atrial fibrillation.  
In short, aspirin is effective in a wide range of ischemic disease. (1994) 
According to the AHA/ACC guidelines for secondary prevention for patients with coronary and 
other atherosclerotic vascular disease, “Start aspirin 75 to 162 mg/d and continue indefinitely in all 
patients unless contraindicated”. (Smith, Allen et al. 2006) Thus, aspirin therapy, unless contraindicated, 
is regarded as a primary treatment for PCI patients. 
2.1.2 Clopidogrel and Ticlopidine 
Whereas aspirin is a relatively weak anti-platelet agent because it inhibits only one of several platelet 
aggregation pathways, i.e. thromboxane A2, the thienopyridines (ticlopidine and clopidogrel) are another 
type of more potent anti-platelet agents. They block adenosine diphosphate (ADP) and thus irreversibly 
inhibit platelet aggregation. Importantly, they act additively or synergistically with aspirin through 
complementary and independent mechanisms. (Sharis, Cannon et al. 1998)  
Ticlopidine has been shown to be clinically effective in reducing adverse cardiac events in 
placebo-controlled studies. However, it has rare but potentially serious adverse effects: neutropenia, 
thrombotic thrombocytopenic purpura, bone-marrow depression, rash and diarrhea. Clopidogrel is 
chemically related to ticlopidine. Of note, it is safer and better tolerated than ticlopidine. (Bertrand, 
Rupprecht et al. 2000)  Moreover, its efficacy in preventing subacute stent thrombosis and peri-procedural 
ischemia is at least as good as ticlopidine. (Bertrand, Rupprecht et al. 2000; Muller, Buttner et al. 2000; 
Bhatt, Bertrand et al. 2002)  Thus, clopidogrel has essentially replaced ticlopidine in this setting. 
CAPRIE, a randomized, blinded, international trial, was conducted to assess the relative benefit of 
clopidogrel (75 mg once daily), compared with aspirin (325 mg once daily) in reducing the risk of a 
composite outcome cluster: ischemic stroke, myocardial infarction, or vascular death. (1996) A total of 
19,185 patients with recent ischemic stroke, recent myocardial infarction, or peripheral arterial disease 
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were recruited over 3 years, with a mean follow-up of 1.91 years. The clopidogrel treatment had a modest 
yet statistically significant better effect than aspirin in terms of the outcome cluster (5.32% vs. 5.83%, 
P=0.043). There were no major differences in terms of safety.  
With particular relevance to use of DES, the combination of aspirin and clopidogrel is associated 
with a lower risk of subacute stent thrombosis than a single agent. The results from the Percutanous 
Coronary Intervention Clopidogrel in Unstable Angina to Prevent Recurrent Events (PCI-CURE) study 
showed that combination therapy with clopidogrel and aspirin was superior to aspirin alone in terms of 
the risk of major ischemic adverse events (RR=0.70, 95% CI 0.50-0.97, P=0.03). There was no significant 
difference in major bleeding between the groups (p=0.64). (Mehta, Yusuf et al. 2001) In contrast, the 
CURE study reported 38% more major bleeding in the Clopidogrel group than in the placebo group (3.7% 
vs. 2.7%, P=0.001) (Yusuf, Zhao et al. 2001).  Thus, although combination therapy with aspirin and 
clopidogrel reduces the risk of adverse cardiac events following PCI, there is also the potential for a 
higher incidence of major bleeding with this treatment regimen. 
On the basis of available evidence, the AHA/ACC guidelines for secondary prevention for 
patients with coronary and other atherosclerotic vascular disease state: “Start and continue clopidogrel 75 
mg/d in combination with aspirin for up to 12 months in patients after acute coronary syndrome or 
percutaneous coronary intervention with stent placement (≥1 month for bare metal stent, ≥3 months for 
sirolimus-eluting stent, and ≥6 months for paclitaxel-eluting stent)”. (Smith, Allen et al. 2006)  Whether 
long clopidogrel and aspirin therapy following PCI (i.e. 1 year and beyond) results in improved patient 
outcomes is currently under investigation. 
2.1.3 Beta Blockers 
Numerous secondary prevention studies have shown that beta blockers reduce the risk of death, and re-
infarction after myocardial infarction. It is also hypothesized that beta blockers provide a complementary 
benefit after successful PCI procedures. Chan et al. investigated the effect of beta blockers on mortality 
 8 
after successful elective PCI among of 4,553 patients in the Cleveland Clinic Foundation registry.  Using 
propensity analysis, beta blockers had an independent protective effect for one-year survival after PCI 
(hazard ratio=0.63, 95% CI: 0.46-0.97, p=0.0054). Results also showed that beta blockers are associated 
with improved survival in most subgroups. (Chan, Quinn et al. 2002) 
From a national cohort of 115,015 patients aged 65 years or older who survived hospitalization 
with a confirmed acute MI from 1994 to 1995, 45,308 patients did not have contraindications to beta 
blockers. Of these patients, 50% had beta blockers prescribed at discharge.  After adjusting for potential 
confounders, beta blockers were associated with a 14% lower risk for one-year mortality.  The protective 
effect was present in subgroups defined by age, gender, left ventricular ejection fraction. (Krumholz, 
Radford et al. 1998)  
Although most studies have shown a beneficial effect of beta blockers among most subgroups of 
patients, (Krumholz, Radford et al. 1998; Chan, Quinn et al. 2002) some studies have shown that beta 
blockers reduce cardiac output and thus decrease renal blood flow. (Wilkinson 1982) 
Despite the compelling clinical evidence for the beneficial effect of beta blocker therapy, a 
surprisingly low prescription at discharge has been reported. (Krumholz, Radford et al. 1998) In addition, 
variation in beta blocker use by state is very large, ranging from 30.3% to 77.1%. Demographic and 
clinical variables appear to explain little of this variation. Regarding the AHA/ACC guidelines for 
secondary prevention for patients with coronary and other atherosclerotic vascular disease, the 
recommendation for beta blocker therapy is: “Start and continue indefinitely in all patients who have had 
myocardial infarction, acute coronary syndrome, or left ventricular dysfunction with or without heart 
failure symptoms, unless contraindicated. Consider chronic therapy for all other patients with coronary 
or other vascular disease or diabetes unless contraindicated.” 
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2.1.4 ACE Inhibitors 
Angiotensin-converting enzyme inhibitors (ACE inhibitors) have been shown to be one of the most 
important treatments for cardiovascular disease. ACE inhibitors attenuate the progressive process of left 
ventricular (LV) remodeling and thus improve survival. These agents are associated with improved 
clinical outcomes in a broad spectrum of patients with preserved left ventricular dysfunction. 
(Investigators 1992; Pfeffer, Braunwald et al. 1992; Kober, Torp-Pedersen et al. 1995)  
The Heart Outcomes Prevention Evaluation (HOPE) study examined the effect of an ACE 
inhibitor, ramipril, versus placebo in patients who were at high risk for cardiovascular events but who did 
not have left ventricular dysfunction or heart failure. A total of 9,297 patients were recruited in the study 
– all had evidence of vascular disease or diabetes plus one other cardiovascular risk factor and were not 
known to have a low ejection fraction or heart failure. They were randomly assigned to receive ramipril 
(10 mg once per day orally) or matching placebo for a mean of five years. Treatment with ramipril 
resulted in lower rates and risks of: (i) death from cardiovascular causes (6.1% vs. 8.1%, RR, 0.74; 
P<0.001); (ii) myocardial infarction (9.9% vs. 12.3%, RR, 0.80; P<0.001); (iii) death from any cause 
(10.4% vs. 12.2%, RR, 0.84; P=0.005); (iv) revascularization procedures (16.3% vs. 18.8%, RR, 0.85; 
P<0.001); (v) cardiac arrest (0.8% vs. 1.3%, RR, 0.62; P=0.02); and (vi) heart failure (9.1% vs. 11.6%, 
RR, 0.77; P<0.001). (Yusuf, Sleight et al. 2000)  These data provide compelling evidence for the 
effectiveness of ACE Inhibitors. Regarding the AHA/ACC guidelines for secondary prevention for 
patients with coronary and other atherosclerotic vascular disease, the recommendation for beta blocker 
therapy is: “Start and continue indefinitely in all patients with left ventricular ejection fraction ≤ 40% and 
in those with hypertension, diabetes, or chronic kidney disease, unless contraindicated. Consider for all 
other patients. Among lower-risk patients with normal left ventricular ejection fraction in whom 
cardiovascular risk factors are well controlled and revascularization has been performed, use of ACE 
inhibitors may be considered optional.” 
 10 
2.1.5 Statins 
Statins are a group of drugs that reduce LDL cholesterol in the blood by inhibiting HMG-CoA reductase. 
The Scandinavian Simvastatin Survival Study was the first clinical trial to demonstrate conclusively that 
long-term statin use substantially reduced the risk of death from all causes, as well as from cardiac events 
(Strandberg, Pyorala et al. 2004). Subsequent trials, including LIPID, CARE, WOSCOPS, AFCAPS HPS, 
indicate the tolerability of long-term daily statin therapy and efficacy for a broad range of cardiovascular 
diseases (1998; Downs, Clearfield et al. 2001; Forster, Stewart et al. 2002; Heart Protection Study 
Collaborative 2002; Shepherd, Blauw et al. 2002).  
The efficacy of statins on secondary prevention after PCI has also been investigated. Serruys et 
al. carried out a randomized trial to assess whether treatment with fluvastatin reduced risk of major 
adverse cardiac events (MACE) for patients who had undergone PCI.(Serruys, de Feyter et al. 2002) A 
total of 1,677 patients with stable or unstable angina or silent ischemia following successful completion 
of their first PCI, and having baseline total cholesterol levels between 135 and 270 mg/dL (3.5-7.0 
mmol/L) and fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) were randomly assigned to 
receive fluvastatin (80 mg/d), or matching placebo (n = 833) at hospital discharge for 3 to 4 years. 
Fluvastatin treatment significantly increased MACE-free survival time (P =0.01). Specfically, the risk of 
at least one MACE was decreased from 26.6% to 21.4% (RR, 0.78; 95% confidence interval, 0.64-0.95; P 
=0.01). This protective effect was consistent among different baseline total cholesterol levels (above and 
below the median). These results strongly support the conclusion that fluvastatin significantly reduces the 
risk of major adverse cardiac events in patients with average cholesterol levels undergoing their first 
successful PCI. There is no specific recommendation about statins in AHA/ACC guidelines for secondary 
prevention for patients with coronary and other atherosclerotic vascular disease. But the goal for lipid 
control becomes higher than before: “LDL-C should be <100 mg/dL; Further reduction of LDL-C to <70 
mg/dL is reasonable.If baseline LDL-C is 100 mg/dL, initiate LDL –lowering drug therapy. If on-
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treatment LDL-C is 100 mg/dL, intensify LDL –lowering drug therapy (may require LDL –lowering drug 
combination).” 
2.1.6 Summary 
Therefore, on balance, the five classes of drugs reviewed above provide strong evidence of efficacy for 
primary or secondary intervention of CVD events. However, considerable variability in clinical practice 
still exists among patients receiving PCI.  Of the 5 classes of drugs reviewed, specific AHA/ACC clinical 
guidelines exist for four of the 5 (aspirin, thienopyridines, beta blockers, ACE inhibitors). At present, the 
greatest degree of variability and uncertainty appears to exist with respect to universal versus selected use 
of statins following PCI, and in the presence of aggressive secondary prevention with other classes of 
medical therapy.  Thus, this important clinical issue was selected for investigation in this dissertation.  To 
reiterate, the primary research question investigated was:  
 Among patients who undergo successful PCI procedures and receive: (i) aspirin; (ii) 
thienopyridines; and (iii) one or more cardiovascular protective medications (ACE inhibitors, beta 
blockers, or calcium channel blockers), does the addition of post-discharge statin therapy provide 
additional clinical benefit? 
2.2 TREATMENT WITH MULTIPLE STENTS VS. A SINGLE LONG STENT 
When more than one stent is implanted into the coronary arteries, the distal part of the stents can be either 
overlapped or not overlapped. The scenarios that typically require stent overlapping are excessive lesion 
length, incomplete lesion coverage, or endoluminal injury or marginal dissection requiring additional 
stent scaffolding beyond the margins of the initial stent.  Thus, stent overlapping may be performed for 
both lesion morphology (i.e. lesion length) and suboptimal PCI dilation results with the initial stent 
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placed. When overlapping is performed, there are no strict rules about the length, usually about 2-4 mm in 
contemporary clinical practice.  
There is large variation in the rate of stent overlapping across different clinical sites or countries, 
ranging from 15% to 36%. (Schofer, Schluter et al. 2003; Kereiakes, Wang et al. 2006; Qiao, Hou et al. 
2006)  Of note, there are little data available to explain the reasons or consequences for this large 
variation. The characteristic of patients, physicians, hospitals, and clustering of districts may all be 
possible explanations.  The pros and cons of stent overlap have been under debate since the bare metal 
stent era and continue today, as summarized below.  
2.2.1 Bare Metal Stent 
Each type of stent device, whether bare metal or drug-eluting, has its metal platform and polymer. 
It is not clear whether they have same effect in terms of short and long clinical outcomes. Ellis et al. 
assessed the risk of restenosis after placement of Palmaz-Schatz stents in the early 1990s. (Ellis, Savage et 
al. 1992) The results discouraged placement of multiple/overlapping stents. Restenosis occurred at 64% 
of sites when multiple stents were implanted, while only 30% of sites had restenosis for single stent 
placement. One limitation of this study was that the follow up was only an average of 5 months. Another 
relatively short (6-month) follow-up study reported a higher rate of restenosis among patients with 
overlapping stent treatment when compared with one single long stent (35% vs. 29%, p>0.05). (De 
Scheerder, Wang et al. 1998) A study by Kastrati et al, including 2,736 consecutive patients treated with 
bare metal stent placement, assessed six-month and one-year event rates. (Kastrati, Elezi et al. 1999) 
Results showed that overlapping of stents is a risk factor of restenosis and late lumen loss, independent of 
lesion length and number of stents (p=0.006 for restenosis; p=0.002 for late lumen loss).  
In contrast, Lee et al. reported a comparable effect for stent overlapping. (Lee, Jang et al. 2004) 
Thirty-two patients received two overlapping stents, and 32 patients received one long stent. The two 
groups had a similar rate of MACE (36% vs. 29%, p=0.56) and six-month restenosis (39% vs. 41%, 
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p=0.91).  Thus, with respect to bare metal stents, some but not all studies suggest that multiple 
overlapping stents may be associated with a higher risk of restenosis and MACE.  What is unknown is 
whether this higher risk, if present, is due to strategy of overlapping per se or because stent overlap with 
multiple stents was performed because of suboptimal result with the initial stent placed. 
2.2.2 Drug Eluting Stents (DES)  
With the introduction of DES, assessment of the merit (or hazard) of overlapping stents becomes even 
more complicated. Specifically, for DES, the overlapped stent metal can serve as a stimulus for 
neointimal proliferation. On the other hand, the drug elution based on the stents will suppress the 
neointimal growth. Animal studies have shown that overlapped segments exhibit delayed healing when 
compared with proximal and distal nonoverlapping segments for both drug-eluting stents and bare-metal 
stents. (Finn, Kolodgie et al. 2005) Kereiakes et al, pooled five clinical trials (SIRIUS, E-SIRIUS, C-
SIRIUS, DIRECT, SVELTE). (Kereiakes, Wang et al. 2006) A total of 575 patients were treated with 
overlapped stents (337 sirolimus-eluting stent, 238 bare metal stent) and a total of 1,162 patients were 
treated with single stents (697 sirolimus-eluting stent, 465 bare metal stent). Analyses were stratified on 
the two stent types.  Results showed that stent overlap was associated with a greater late lumen loss. The 
risk of target vessel revascularization was significantly higher in both overlapped stent groups (29.4% vs. 
19.8%, p<0.01 for bare metal stent; 9.5% vs. 5.0% for sirolimus-eluting stent).  
However, other studies have shown that overlapping-stents is as feasible and effective as non-
overlapping stents.  Chu et al. compared the clinical outcomes among 55 patients who received 
overlapping and 39 patients who received non overlapping sirolimus-eluting stents. (Chu, Kuchulakanti et 
al. 2006) Results showed that event-free survival rate was similar between the two groups (P=0.87). No 
difference was found between the two treatment groups for 30-day and 6-month revascularization, death, 
Q-wave MI, Non-Q-wave MI, and stent thrombosis. The in-hospital complication rate was also similar 
except for a higher rate of Non-Q-wave MI with overlapped-stent treatment (7.7% vs. 23.6%, p=0.04). 
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This higher rate of myonecrosis is due to periprocedural side branch compromises, including side branch 
occlusion (19.4% vs. 5.8%, p=0.01), narrowing (61.3% vs. 29.2%, p<0.001), and TIMI flow reduction 
(54.8% vs. 19.0%). Kereiakes et al. also reported overlapping sirolimus-eluting stents provided similar 
magnitude of restenosis benefit as observed for single-stent-treated patients. (Kereiakes, Wang et al. 
2006) An ultrasound study of eight patients did not find any significant quantitative changes in 
intravascular measurements within the overlapped segment at 1-year follow-up. (Munoz, Abizaid et al. 
2004) 
Thus, similar to bare metal stents, the use of multiple overlapping DES has yielded mixed results 
in terms of risk of restenosis and MACE.  On balance, there is little to no persuasive evidence indicating a 
clinically favorable effect of stent overlapping despite the fact that it occurs relatively frequently in real-
world clinical practice of PCI.  
2.2.3 Heterogeneous Overlapping 
When overlapping DESs are implanted, the drug dose would be expected to double at the 
overlapping location. If different types of DES are overlapped, the different drug can interact with each 
other through the same or different mechanisms.  
Kang et al. performed a study among 47 consecutive patients receiving two DESs for diffuse long 
lesions. (Kang WC 2007) A total of 14 patients received two sirolimus and paclitaxel-eluting stents; 13 
patients received two sirolimus-eluting stents; 20 patients received two paclitaxel-eluting stents. The 
endpoint was neointimal hyperplasia at the overlapping site based on 9-month follow-up angiographic 
and IVUS examination. The results showed that overlapping of different DES had a similar effect on the 
suppression of neointimal hyperplasia as compared to overlapping of two of the same DES. The 
conclusion arrived at is the same as a study conducted by Burzotta et al. (Burzotta, Siviglia et al. 2007) 
However, their results also showed that overlapping of DES and BMS should be avoided because this 
combination results in a higher rate of MACE as compared to an approach of overlapping of two. 
 15 
2.2.4  Summary 
In summary, results are mixed on the effect of overlapping stents. Some studies suggest an adverse effect; 
others indicate no effect, and a few may suggest a favorable effect. More definitive analyses are needed, 
particularly with respect to whether the use of stent overlapping appears to be a planned (a priori) strategy 
as opposed to a consequence (ad hoc response) to lesion dilation complications.  Thus, this important 
clinical issue was selected for investigation in this dissertation.  To reiterate, the primary research 
question investigated was:  
 What is the effect on patient outcome of the use of single versus multiple stents for atherosclerotic 
lesions that are of length 10-32 mm and, theoretically, based on lesion length and available stent sizes, 
can be treated with a single stent?   
2.3 POSTDILATION 
During the evolution of stent delivery systems, “semi-compliant” balloons have been increasingly used 
for stent deployment.  This enables a higher pressure during the implantation than earlier generation 
“compliant” balloons. Therefore, use of postdilation has concomitantly decreased when compared to the 
era of balloon-expandable stents, which were delivered through compliant balloons. However, researchers 
soon learned that postdilation may still be needed in order to decrease the risk of target vessel 
revascularization and thrombosis, and possibly other long term clinical outcomes. 
In common clinical practice, PCI procedures are guided by coronary angiography.  With this 
approach, a catheter is inserted into the femoral or radial artery, and the degree of narrowing is visually 
identified from an X-ray image. More recently, with the introduction of intravascular ultrasound (IVUS), 
researchers can assess the post-procedural stenting with two powerful measures: minimal stent area 
(MSA) and minimal stent diameter (MSD). It is well established that larger post-procedural stent 
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dimensions are associated with lower rates of restenosis and target vessel revascularization. (Kuntz, 
Safian et al. 1992; Hoffmann, Mintz et al. 1998; Kasaoka, Tobis et al. 1998; de Feyter, Kay et al. 1999; 
Sonoda, Morino et al. 2004)  In the SIRIUS IVUS study, a substudy of the SIRIUS trial, MSA was highly 
correlated with minimum lumen area (MLA) at 8-month follow up for both SES and BMS (r=0.8 for SES, 
p<0.0001; r=0.65 for BMS, p<0.0001). (Sonoda, Morino et al. 2004)  Thus, the extent to which larger 
post-procedural stent dimensions can be obtained from PCI, whether visualized or guided by coronary 
angiography and IVUS, remains a desired clinical goal.  
2.3.1 Postdilation and Restenosis 
The CRUISE (Can Routine Ultrasound Influence Stent Expansion?) study, a substudy of the Stent Anti-
thrombotic Regimen Study (STARS), randomized 497 patients to either IVUS-guided stent implantation 
or standard stent implantation. The IVUS-guided group performed postdilation with noncompliant 
balloons at high pressures and used large balloons when needed. The IVUS-guided group had a larger 
minimal lumen diameter (2.9±0.4 versus 2.7±0.5 mm, p<0.001), a larger minimal stent area (7.78±1.72 
versus 7.06±2.13 mm2, p<0.001), and lower risk of target vessel revascularization (8.5% versus 15.3%, 
p<0.05).  These data indicate the clinical value of IVUS above and beyond conventional coronary 
angiography despite the fact that IVUS is infrequently used in clinical practice.  
Nonetheless, even though the use of DES has dramatically reduced the incidence of restenosis, 
target vessel revascularization still occurs in 5% of patients or more.  Even with this relatively low 
background incidence, some studies have shown that postdilation provides supplemental benefit after 
implantation of DES. (Kuntz, Safian et al. 1992; Hoffmann, Mintz et al. 1998; Kasaoka, Tobis et al. 1998; 
de Feyter, Kay et al. 1999; Sonoda, Morino et al. 2004) 
 17 
2.3.2 Postdilation and Thrombosis 
Stent under-expansion remains the major factor associated with stent thrombosis, a catastrophic clinical 
event. Cheneau and colleagues analyzed 7,484 consecutive patients without acute myocardial infarction 
who received stent treatment and underwent IVUS imaging during the intervention. Inadequate 
postprocedure lumen dimensions were significantly associated with subacute stent thrombosis. (Cheneau, 
Leborgne et al. 2003) Fujii et al, carried out a matched case-control study. (Fujii, Carlier et al. 2005) A 
total of 15 patients who had stent thrombosis after SES implantation were matched with 45 control 
patients who did not have stent thrombosis after SES implantation. The stent thrombosis group had 
statistically significant smaller MSA (4.3 vs. 6.2 mm2, p<0.001), less stent expansion (0.65 vs. 0.85, 
p<0.001), and more residual stenosis in the proximal/distal reference vessel (67% vs. 9%, p<0.001). The 
MSA and stent expansion were independent predictors for stent thrombosis. In addition, Uren and 
colleagues reported that under-expansion was associated with ultrasound abnormal finding. (Uren, 
Schwarzacher et al. 2002) 
2.3.3 Size and Pressure 
The dilation force a balloon exerts against a lesion or against a stent may be related to both the balloon 
size and the inflation pressure.  
Researchers assessed the effect of different inflation pressure on stent expansion. A porcine 
coronary model of 30 pigs assessed the effect of different deployment pressure: 4 atm (group one), 8 atm 
(group two), 14 atm (group three). (De Scheerder, Wang et al. 1998) Imperfect stent alignment was found 
in 8 coronary arteries: 7 in group one, 1 in group 2, 0 in group 3. Cheneau and colleagues assessed the 
relationship between delivery pressure and expansion for sirolimus-eluting stents (Cypher). (Cheneau, 
Satler et al. 2005) Stent expansion was 72% after 14 atm balloon inflation, 90% after 20 atm balloon 
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inflation, and 90% at the end of procedure with optional postdilating with 0.5 mm larger balloon. The 
degree of expansion may impact the late occurrence of restenosis. 
Despite the lack of randomized clinical trial to support that aggressive dilation is effective in 
preventing restenosis, stent thrombosis, and long-term adverse clinical outcomes, evidence from many 
observational studies suggest this possibility. However, in practice, due to physician strategy, imaging 
technique used (e.g. coronary angiography), complexity of some lesions being treated, and clinical 
circumstances of the patient (e.g. acute MI), very few patients actually receive optimal stent dilation. 
Indeed, Cheneau et al. reported that only 15% of patients treated with the SES delivery system achieved 
optimum stent deployment (MSA/RLA>80%) by IVUS measurements. (Cheneau, Satler et al. 2005) 
2.3.4 Summary 
In summary, there is considerable variation in the use of postdilation after stent implantation, and 
moreover, whether this strategy appreciably influences patient outcomes.  Thus, this important clinical 
issue was selected for investigation in this dissertation.  To reiterate, the primary research question 
investigated was:  
After initial PCI dilation of one or more obstructive lesions, does lesion post-dilation (i.e. for 
presumed optimal stent expansion) significantly impact patient outcomes?  In addition, does the effect of 
this procedural approach vary among patients who present with acute myocardial infarction (MI) versus 
those presenting without acute MI? 
 
 19 
3.0  POST-DISCHARGE STATIN FOR PREVENTION OF CARDIAC EVENTS FOR 
PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 
 
Zhijiang Zhang, MS;† Roslyn A. Stone, PhD;¶ Oscar C. Marroquin, MD;‡  
                     Joel L. Weissfeld, MD, MPH;† and Kevin E. Kip, PhD† 
 
 
 
 
       † Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania;   
       ¶ Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania; and 
      ‡ Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 
 
 
(Manuscript in Preparation) 
 
 
 20 
3.1 ABSTRACT 
Background: Statins have proven to be effective in reducing mortality and cardiac events for a 
broad range of cardiovascular patients. However, evidence about their efficacy for routine use among 
patients undergoing percutaneous coronary intervention (PCI) is still limited. The rapid advancement in 
PCI technology and introduction of new adjunctive medicine make it necessary to assess the effect of 
statin therapy on adverse cardiac events among patients undergoing PCI procedure and receiving 
adjunctive medicine. 
Methods: Patients were evaluated from the National Heart, Lung, and Blood Institute (NHLBI) 
Dynamic registry recruitment Wave 4 (2004) and Wave 5 (2006), which is a multi-center prospective 
observational study. Patient eligibility criteria for this analysis included receipt of aspirin, thienopyridines 
and cardiovascular protective medications (angiotensin-converting enzyme inhibitors, beta blockers, or 
calcium channel blockers) after PCI procedure with at least one stent implanted. Baseline characteristics, 
procedure and lesion information were collected. Adverse cardiac event risks, including death, MI, 
repeated PCI, CABG, stent thrombosis, repeated PCI/CABG, death/MI, death/MI/CABG, MACE,  were 
compared at one-year follow up between patients receiving post-discharge statin and those who did not. 
Results: From Dynamic Registry Wave 4 and Wave 5, a total of 3270 patients were included in 
this analysis. Of these 3270 patients, 2782 patients (85%) were taking post-discharge statin, and 488 
patients (15%) were not taking post-discharge statin. At one-year follow up, post-discharge statin 
treatment was significantly associated with lower risk of death (HR=0.51, 95% CI: 0.30-0.86, p=0.01), 
death/MI (HR=0.60, 95% CI: 0.40-0.92, p=0.02), and death/MI/CABG (HR=0.64, 95% CI: 0.44-0.94, 
p=0.02). The association between postdischarge statin and MACE was of borderline statistical 
significance (HR=0.76, 95% CI: 0.59-1.00, p=0.05). No significant association was found between post-
discharge statin and MI (HR=0.72, 95% CI: 0.38-1.37, p=0.32), repeat PCI (HR=0.85, 95% CI: 0.60-1.19, 
p=0.33), CABG (HR=0.99, 95% CI: 0.41-2.44, p=0.99), stent thrombosis (HR=0.54, 95% CI: 0.14-2.02, 
p=0.36), or repeat PCI/CABG (HR=0.86, 95% CI: 0.62-1.19, p=0.36). 
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Conclusions: Among patients who already received aspirin, thienopyridines and cardiovascular 
protective medications (ACE inhibitors, beta blockers, or calcium channel blockers) after PCI procedure, 
post-discharge statin treatment was associated with a significantly reduced risk of death, death/MI and 
death/MI/CABG, but not significantly associated with reduced risk of other adverse events.  These results 
support routine use of statin therapy after PCI. 
 
Key words: Percutaneous coronary intervention, statin, mortality, adjunctive medication, stent 
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3.2 INTRODUCTION 
Percutaneous coronary intervention (PCI) has proven to be very effective in treating ischemic symptoms 
due to coronary atherosclerotic narrowing [1, 2]. In the United States, more than one million PCI 
procedures are performed annually, 70–90 percent of which involve implantation of a stent according to 
American Heart Association (AHA).  
Although PCI achieves immediate symptoms relief in 9 of 10 properly selected patients, these 
patients remain at increased risk for cardiac events. It is estimated that 40% of patients have major 
adverse cardiac events (MACE) in 5 years after PCI procedure and 66.7% have MACE in 10 years after 
PCI procedure [3]. Therefore, most patients also receive adjunctive medicine after PCI procedure, for 
example, aspirin, thienopyridines (clopidogrel or ticlopidine) and cardioprotective medications, such as 
angiotensin-converting enzyme (ACE) inhibitors, beta blockers, or calcium channel blockers.   
Secondary prevention trials of statins (HMG-CoA reductase inhibitors) have shown a 25% to 
30% reduction in ischemic cardiovascular events at long-term follow up [4-6]. However, few data are 
available to assess whether routine use of statins provide complementary benefit for patients who are 
receiving other adjunctive medication treatment after PCI.  
To evaluate the effect of post-discharge statin treatment among patients who already received 
aspirin, thienopyridines and at least one type of cardiovascular protective medication (ACE inhibitors, 
beta blockers, or calcium channel blockers) after undergoing PCI, we evalauetd patients in Dynamic 
Registry recruitment Wave 4 (2004) and Wave 5 (2006) cohorts to compare one-year outcomes between 
patients who received a statin prescription after PCI and those who did not receive a statin prescription 
after PCI.  
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3.3 METHODS 
3.3.1 Patient Selection and Data Collection 
The National Heart, Lung, and Blood Institute (NHLBI) Dynamic registry includes 14 sites in Wave 4, 
and 16 sites in Wave 5 as well as a data coordinating center at University of Pittsburgh. Patients 
undergoing PCI by Dynamic Registry investigators were enrolled consecutively. Wave 4 recruited 2112 
patients. Wave 5 recruited 2158 patients. Consecutive enrollment at each site ended when 125 white men 
had been enrolled at the site or 1,600 white patients were enrolled across all sites. Consecutive enrollment 
of women and minorities continued at each site until 200 white patients had been enrolled at the site or 
1,600 white patients were enrolled across all sites. Consecutive enrollment of minority patients, men and 
women, continued until 2,000 patients had been enrolled across all sites. Informed consent was obtained 
to collect information after hospital discharge. To be eligible for this analysis, the patients had to receive 
at least one stent, receive aspirin, thienopyridines and at least one type of cardiovascular protective 
medications (ACE inhibitors, beta blockers, or calcium channel blockers) after PCI procedure. 
On-site research coordinators were trained before the recruitment wave started. Data were 
collected using standard forms. The Dynamic Registry database management system used front-end data 
entry software developed by the data coordinating center. Data were verified and monitored after entry.  
The data were imported into an SAS database to search for logical, chronologic, and data accrual 
inconsistencies. Reports were sent to sites, where corrections might be made after verification.  
Successful lesion dilation was defined as an absolute reduction of at least 20% in lesion severity 
and a final stenosis of <50% (diameter reduction). Partial angiographic success was defined as some but 
not all lesions were successfully treated; total angiographic success was defined as all attempted lesions 
were treated successfully. Procedural success was defined as partial or total angiographic success without 
in-hospital death, myocardial infarction, or emergency coronary artery bypass graft surgery. Myocardial 
infarction was defined by evidence of ≥2 of the following: (1) typical chest pain > 20 minutes, not 
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relieved by nitroglycerin; (2) serial electrocardiograms showing characteristic ST-T changes and/or Q 
waves in ≥2 contiguous leads; (3) serial electrocardiograms showing characteristic ST-T changes and/or 
Q waves in ≥2 contiguous leads; (4) serum enzyme elevation of creatine kinase-MB is more than 5% of 
total creatine kinase. Repeat PCI was categorized according to whether the index lesion (target lesion 
revascularization) or artery (target vessel revascularization) was attempted. Definite stent thrombosis was 
defined as the presence of angiographic thrombus in a stent that had been previously successfully 
deployed accompanied by an acute coronary syndrome. Angiographic thrombus was defined as complete 
occlusion with a stent diameter stenosis <30% or evidence of flow-limiting thrombus within or 
immediately adjacent to the stent. 
3.3.2    Statistical Methods 
Patients were categorized into 2 groups according to whether statin therapy was prescribed at discharge. 
Intergroup differences of continuous variables were analyzed with Student’s t test. Intergroup differences 
of categorical variables were analyzed with chi-square tests. Kaplan-Meier analysis was used to estimate 
the 1-year cumulative incident proportion of each adverse event in each group. Patients were censored at 
the last known date of contact or after the first occurrence of the event of interest. Cox proportional 
hazards regression was used to compare the risk of adverse events between treatment groups during one-
year follow-up. Three subgroup analyses were carried out to assess the effect of post-discharge statin 
therapy including: (i) patients who only received Beta Blocker among the three cardiovascular protective 
medications; (ii) patients who received beta blocker, ACE inhibitor, but no calcium channel blockers; and 
(iii) patients who were not in the above two subgroups.   
A propensity score model was fit by use of logistic regression to adjust for the bias inherent to the 
decision to prescribe post-discharge statin therapy [7-12]. A candidate list of baseline variables was 
included in the propensity score model (refer to Appendix A). A backward approach was used for 
variable selection with p value of 0.40. Inter-group balances on potential confounders were tested again 
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after adjustment for the propensity score. If balance was not achieved for certain covariates, the 
propensity model was refitted by including these covariates in the model. The propensity score was a 
single covariate that was included in the Cox proportional hazards model to control for confounding 
related to imblances in the primary exposure variable. One-year cumulative incident proportions were 
estimates from the Kaplan-Meier analysis for each adverse event in each treatment group. Estimates from 
crude Cox proportional hazards model were used to plot curves of unadjusted cumulative incident 
proportion of death by treatment group. Estimates from the Cox proportioanal hazards model, weighted 
with inverse probability weights (IPW), were used to plot the curve of the weighted cumulative incident 
proportion of death by treatment group.  Specifically,  each patient was weighted by swi (swi=f(xi)/f(xi|zi); 
f(xi), marginal probability of receiving the exposure observed; f(xi|zi), probability of receiving the 
exposure observed conditional on observed covariates) [13]. The proportional hazards assumption of 
constant relative risk over follow-up was evaluated by testing the interaction between time and the 
primary exposure.  All statistical analyses were performed using the SAS program, version.9.1 (SAS 
Institute, Cary, NC). 
3.4 RESULTS 
During the study period, a total of 4270 patients were enrolled in Dynamic Registry recruitment Wave 4 
and Wave 5. Of these 4270 patients, 45 patients (1.1%) died before discharge, 159 patients (3.7%) did not 
receive aspirin description or had missing information, 186 patients (4.4%) did not take clopidogrel or 
ticlopidine at discharge or had missing information, 372 patients (8.7%) did not take any cardiovascular 
protective medications (ACE inhibitors, beta blockers, or calcium channel blockers) or had missing 
information. A total of 3280 patients (77%) were included in this analysis. Of these 3280 patients, 2970 
patients (85%) were taking post-discharge statin, and 540 patients (15%) were not taking post-discharge 
statin. The median follow-up among all patients was 8 months and 79% of patients had at least 6-month 
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follow-up. The proportional hazards assumption of constant relative risk over follow-up was found to be 
upheld. 
Table 3.1 shows the patient demographic, disease history and angiographic characteristics in the 
two treatment groups. Important differences existed between the two groups. Patients receiving post-
discharge statin treatment were more likely to have chest pain at admission (72.2% vs. 66.1%), history of 
hypercholesterolemia (79.2% vs. 66.8%). They were also less likely to be female (31.5% vs. 39.3%), have 
prior CABG (17.2% vs. 20.7%), severe non-cardiac disease (34.7% vs. 39.7%), history of congestive 
heart failure (8.5% vs. 14.9%), and history of hypertension (78.0% vs. 82.6%) or be known to have 
hypercoagulable status (1.7% vs. 4.2%).  
Procedure and lesion characteristics are shown in Table 3.2. Statin recipients were more likely to 
have Acute MI (30.7% vs. 23.8%), be at urgent (32.4% vs. 25.2%) or emergent procedure (12.4%vs. 
9.4%), receive IIb/IIIa receptor antagonist (35.0% vs. 25.1%). The lesion characteristics were similar in 
the two groups except that statin recipients were more likely to have thrombus evidence (16.2% vs. 
9.4%).  
The variables to predict the propensity score from the logistic model are shown in Appendix A. 
The c statistic of the propensity model was 0.69, indicating a probability of 0.69 that a randomly selected 
post-discharge statin recipient has a larger propensity score than a randomly selected patient who did not 
receive post-discharge statin. The mean propensity score in the statin group was slightly higher than the 
no statin group (0.86 vs. 0.78). The distribution of propensity scores among the two treatment groups is 
shown in Figure 3.1.  
 Cumulative incident proportions for each adverse event at one-year follow up were estimated 
with Kaplan-Meier method (Table 3.3). Patients receiving post-discharge statin had lower proportions of 
each adverse event than patients who did not (death, 2.7% vs. 6.9%; MI, 2.2% vs. 3.1%, repeat PCI, 
10.2% vs. 11.1%; CABG, 1.6% vs. 1.8%; stent thrombosis, 0.4% vs. 0.6%) and composite endpoints 
(repeat PCI/CABG, 11.5% vs. 12.3%; death/MI, 4.7% vs. 9.5%; death/MI/CABG, 6.0% vs. 11.0%; 
MACE, 14.6% vs. 19.8%). Figure 3.2 is the curve of death incidence in the two treatment groups 
 27 
produced from crude Cox proportional hazards model, estimated as 1- the estimated survival probability. 
Post-discharge statin group had a lower death incidence than the no post-discharge statin group. Figure 
3.3 is the curve of death incidence produced from Cox proportional hazards model weighting with IPW, 
which shows the adjusted incidence of death among statin group, estimated as 1- adjusted survival 
probability, was lower than among no statin group. The estimated hazard ratios from Cox proportional 
hazards model are shown in Table 3.3. After adjustment with propensity scores, post-discharge statin 
treatment was significantly associated with reduced risk of death (HR=0.51; 95% CI, 0.30-0.86, p=0.01), 
composite endpoints of death/MI (HR=0.60; 95% CI, 0.40-0.92, p=0.02), composite endpoints of 
death/MI/CABG (HR=0.64; 95% CI, 0.44-0.94, p=0.02). The association between postdischarge statin 
and risk of MACE is of borderline significance (HR=0.76; 95% CI, 0.59-1.00, p=0.05). It is also non-
significantly associated with a lower risk of MI, repeat PCI, CABG, stent thrombosis, and repeat 
PCI/CABG.  
Results of subgroups analysis among patients who took only Beta Blocker, no ACE inhibitor or 
Calcium channel blockers are shown in Table 3.4. Post-discharge statin use was associated with lower 
risk of all adverse events, except for a higher risk of CABG. None of these differences is statistically 
significant. 
Results of subgroups analysis among patients who took beta blocker, ACE inhibitor, but no 
calcium channel blockers are shown in Table 3.5. Post-discharge statin use was associated with lower risk 
of all adverse events, except for a slightly higher risk of death (HR=1.01, 95% CI: 0.36-2.83, p=0.99). 
None of these differences is statistically significant. 
Results for the remaining patients are shown in Table 3.6. Post-discharge statin use was 
associated with a significantly reduced risk of death (HR=0.34, 95% CI: 0.15-0.79, p=0.01). Post-
discharge statin treatment was non-significantly associated with reduced risk of all adverse events 
considered, except for a non-significantly higher risk for repeat PCI (HR=1.28, 95% CI: 0.60-2.75, 
p=0.53) and repeat PCI/CABG (HR=1.42, 95% CI: 0.67-3.03, p=0.36). 
 28 
 Figure 3.1 Boxplot of propensity scores in no statin group and statin group* 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower quartile  
            (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher than   
Q3. The two whiskers below and above the shaded box indicate the smallest and  
largest values that are not outliers. 
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Figure 3.2 Cumulative incidence proporiton of death estimated from crude Cox  
proportional hazards model for statin group and no statin group
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Figure 3.3 Cumulative incidence proportion of death estimated from weighted Cox  
proportional hazards model for statin group and no statin group
 
3.5 DISCUSSION 
 
 The present study assessed whether post-discharge statin treatment was associated with reduced cardiac 
adverse event rates for patients already receiving adjunctive medicine after PCI procedure. Results 
showed that post-discharge statin treatment was associated with lower cumulative incident proportion for 
each adverse event, including death, MI, repeated PCI, CABG, stent thrombosis, Repeated PCI/CABG, 
death/MI, death/MI/CABG, MACE. After propensity score adjustment for predictors of statin use, post-
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discharge statin treatment was significantly associated with a reduced risk of mortality and composite 
endpoints of death/MI, and death/MI/CABG. Post-discharge statin use also was associated with lower risk 
of MACE, but it was of borderline statistical significance. Similar patterns of risk reduction were 
observed in the three subgroups of patients considered, except for death among patients who took beta 
blockers and ACE inhibitors, but no calcium channel blockers. In this subgroup, the hazard ratio of death 
was non-significantly elevated. 
It has been well established that statins reduce blood cholesterol level [4-6]. Beyond that, statins 
also have favorable effects on platelet adhesion [14, 15], stent thrombosis [16-18], endothelial function 
[19-24], plaque stability and inflammation [25-30]. All these functions can possibly contribute to the 
mortality benefit among PCI patients. Our finding showed a strong protective effect against mortality at 
one-year follow up (HR=0.51, 95% CI: 0.30-0.86, p=0.01). The magnitude is comparable to a six-month 
follow-up study by Chan et al. (HR=0.65, 95% CI: 0.42-0.99, p=0.04)[31]. The difference between the 
two studies is that Chan et al. assessed the effect of statin administered before PCI procedure, while our 
study examined the effect of post-discharge statin treatment. They excluded severe patients with acute 
MI, recent MI (within 7 days of procedure), or cardiogenic shock. Our study excluded patients who did 
not receive aspirin, or thienopyridines, or cardiovascular protective medications (ACE inhibitors, beta 
blockers, calcium channel blockers). Kasai et al. also reported a similar magnitude of long-term efficacy 
of statin treatment at the time of PCI procedure with an average follow-up of 11 years in a Japanese 
population [32]. Statin treatment was associated with a significant reduction in all cause mortality 
(HR=0.54, 95% CI: 0.29-0.99, p=0.048) and cardiac death (HR=0.24, 95% CI: 0.07-0.80, p=0.02). Some 
previous clinical trials with small sample size did not find a statistically significant association between 
statin and mortality risk [33, 34].  
No studies until today have confirmed the efficacy of routine use of statins on restenosis after PCI 
procedure, although lab experiments provided some evidence that statins prohibit smooth muscle 
proliferation. The PREDICT trial was a multicenter, randomized, double-blind trial between 1992 and 
1994, aiming to assess restenosis benefit with pravastatin (40 mg/day) for 6 month after successful 
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balloon angioplasty (PTCA) [34]. Minimal lumen diameter, assessed by quantitative coronary 
angiography, was not different at 6-month follow-up (pravastatin 1.54±0.66mm vs placebo 
1.47±0.62mm). The restenosis rate was 39.2% in pravastatin group and 43.8% in placebo group (p=0.26). 
The Fluvastatin Angiographic Restenosis (FLARE) was another trial designed to evaluate restenosis 
benefit of statin among patients undergoing successful PTCA (no stent use) [35]. The study was between 
1992 and 1995, similar to PREDICT. Patients were randomized to either placebo or fluvastatin 40mg 
twice daily, which started 2-4 weeks before the procedure. There was no difference in late lumen loss 
(fluvastatin 0.23±0.49mm vs. placebo 0.23±0.52mm, p=0.95), which was measured by quantitative 
coronary angiography. Also no difference was found in angiographic restenosis rate (fluvastatin 28% vs 
placebo 31%, p=0.42). Another earlier trial, Lovastatin Restenosis Trial, reported that lovastatin (40 mg 
orally twice daily) before coronary angioplasty did not prevent or delay restenosis in the first six months 
after the procedure [33]. We did not find a statistically significant association between post-discharge 
statin treatment and repeated PCI (HR=0.85, 95% CI: 0.60-1.19, p=0.33), or repeated PCI/CABG 
(HR=0.86, 95% CI: 0.62-1.19, p=0.36). This could be due to the fact that DES decreases the risk of repeat 
PCI to the extent that the event rate is too small to detect a clinically importance effect of postdischarge 
statin on the risk of this event.  
Previous studies reported beneficial effect of statin on composite endpoints among PCI patients. 
FLARE trial reported a lower incidence of death/MI in fluvastatin group when compared to placebo 
group (1.4% vs. 4.0%, log rank P=0.025), but not for death/MI/CABG or death/MI/CABG/repeated 
PTCA [35]. Serruys et al. reported that post-discharge statin treatment was associated with a significant 
reduction in composite endpoint of cardiac death, nonfatal myocardial infarction or reintervention 
procedure (HR=0.78, 95% CI: 0.64-0.95, p=0.01) [36]. After excluding reinterventions from the 
composite endpoint, the protective effect became stronger (HR=0.67, 95% CI: 0.54-0.84, p<0.001). Our 
study found a significant protection effect for composite endpoints of death/MI, death/MI/CABG.  
There are limitations for our study. First, the present study design is a prospective observational 
study. Although we adjusted for a wide array of factors associated with statin use, it is still possible that 
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unknown confounders (residual confounding) may have biased risk estimates. Second, the number of 
some types of adverse cardiac events, such as stent thrombosis and CABG surgery, was small, and we had 
limited power to detect clinically important effects for these events. Third, only prescription information 
was collected without knowing patient adherence to the regimen. Crossover between the two groups 
might also occur. However, we do not have reason to believe the crossover is differential. Both poor 
adherence and non-differential crossover tend to underestimate the association between post-discharge 
statin and adverse cardiac events.  
3.6 CONCLUSIONS 
Among patients who already received aspirin, thienopyridines and cardiovascular protective 
medications (ACE inhibitors, beta blockers, or calcium channel blockers) after PCI procedure, post-
discharge statin treatment was associated with a significantly reduced risk of death, death/MI, 
death/MI/CABG, and MACE, but not significantly associated with reduced risk of other adverse events.  
These results support routine use of statin therapy after PCI. 
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Table 3.1 Patient demographics, disease history, and angiographic characteristics between the two 
treatment groups 
 
Characteristics No statin (n=488) 
Statin 
(n=2782)      P† P‡ 
Female, % 39.3 31.5    <0.01 0.97 
Age in years       65.6(12.2)         63.3(11.9)    <0.01   0.98 
Race, % 
   White 
   Black 
   Asian 
   Other 
 
78.5 
17.0 
1.4 
3.1 
 
79.2 
16.1 
3.0 
1.7 
 
0.05 
 
0.25 
Insurance 
    Medicare 
    Other public 
    Private 
    None/self-pay 
 
41.4 
15.8 
39.9 
2.9 
 
35.0 
15.8 
45.5 
3.8 
 
0.04 
 
0.98 
Hispanic, % 7.0 5.0 0.07 0.06 
Prior intervention, % 34.4 32.4 0.38 0.93 
Prior CABG 20.7 17.2 0.06 0.93 
Prior MI 21.7 24.6 0.17 0.96 
Severe non-cardiac disease 39.7 34.7 0.03 0.71 
History of diabetes 36.3 33.5 0.24 0.69 
History of chest pain 55.3 53.7 0.51 0.22 
Chest pain at admission 66.1 72.2   <0.01 0.90 
History of CHF 14.9 8.5    <0.01 0.93 
CHF at admission 8.0 5.9 0.07 0.82 
History of hypertension 82.6 78.0 0.02 0.69 
History of hypercholesterolemia 66.8 79.2    <0.01 0.97 
Known hypercoagulable state 4.2 1.7    <0.01 0.45 
Dominance 
   Left  
   Right 
   Balanced 
 
5.9 
87.0 
7.1 
 
8.3 
83.8 
8.0 
 
0.15 
 
0.96 
Vessel disease 
   Single 
   Double 
   Triple  
 
35.1 
29.9 
35.1 
 
35.7 
32.8 
31.5 
 
0.25 
 
0.71 
Cardiac Protective Medications 
   Only ACE 
   Only beta blocker 
   Only calcium channel blocker 
   ACE+beta blocker 
   ACE+calcium channel blocker 
   beta blocker + calcium channel blocker 
   ACE + beta blocker + calcium channel 
blocker 
 
7.4 
38.7 
3.7 
32.0 
3.5 
8.4 
 
6.4 
 
7.1 
32.8 
2.4 
43.1 
1.7 
6.3 
 
6.7 
 
   <0.01 
 
0.32 
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Table 3.1 continued 
Amenable with CABG 74.0 77.5 0.09 0.96 
Amenable with PCI 90.2 89.4 0.63 0.97 
 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention; ACE angiotensin-converting enzyme inhibitors. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 3.2 Procedure and lesion characteristics between the two treatment groups 
Characteristics No statin (n=488) 
Statin 
(n=2782) P value† P value‡ 
Cause of procedure 
   Acute MI 
   Unstable angina 
   Stable angina 
   Asymptomatic CAD 
   Other 
 
23.8 
34.0 
20.3 
15.4 
6.6 
 
30.7 
34.2 
19.8 
11.1 
4.2 
 
<0.01 
 
0.99 
Procedure circumstance 
   Elective 
   Urgent 
   Emergent  
 
65.4 
25.2 
9.4 
 
55.2 
32.4 
12.4 
 
<0.01 
 
0.89 
Procedure site 74.2 76.5 0.26 0.49 
No. of lesions attempted 
1 
2 
3 or more 
 
73.2 
22.8 
4.1 
 
73.8 
21.0 
5.3 
 
0.41 
 
0.95 
IIb/IIIa receptor antagonist 25.1 35.0 <0.01 0.62 
Any lesion >25mm 15.4 15.6 0.90 0.96 
Any lesion previously 
treated  
 
5.9 
 
6.7 
 
0.56 
 
0.58 
Any evidence of thrombus 9.4 16.2 <0.01 0.46 
Any calcification 30.3 27.0 0.13 0.96 
Any ulcerated lesion 13.1 13.6 0.78 0.91 
Any ostial lesion 9.4 8.3 0.41 0.58 
C type AHA/ACC 
classification 29.1 27.5 0.47 0.97 
Angiographic success 
   Yes 
   Partial 
   No 
 
93.0 
2.7 
4.3 
 
93.1 
2.8 
4.1 
 
0.97 
 
0.99 
CAD indicated coronary artery disease; AHA American Heart Association; ACC American College of 
Cardiology.  
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 3.3 One-year cumulative incident proportions (K-M) and hazard ratios of 1-year outcome 
comparing post-discharge statin treatment to no post-discharge statin treatment 
 
Event  N* 
Cumulative incident proportion Hazard 
Ratio† 95% CI P value    No statin     
   (n=488) 
     Statin 
      (n=2792) 
Death 74 6.9% 2.7% 0.51 0.30-0.86 0.01 
MI 62 3.1% 2.2% 0.72 0.38-1.37 0.32 
Repeat PCI    260 11.1% 10.2% 0.85 0.60-1.19 0.33 
CABG 46 1.8% 1.6% 0.99 0.41-2.44 0.99 
Stent thrombosis 14 0.6% 0.4% 0.54 0.14-2.02 0.36 
Repeat 
PCI/CABG    299 12.3% 11.5% 0.86 0.62-1.19 0.36 
Death/MI    131 9.5% 4.7% 0.60 0.40-0.92 0.02 
Death/MI/CABG    169 11.0% 6.0% 0.64 0.44-0.94 0.02 
MACE    387 19.8% 14.6% 0.76 0.59-1.00 0.05 
MI indicates myocardial infarction; PCI percutaneous coronary intervention; CABG coronary artery 
bypass graft surgery; MACE major adverse cardiac event, consited of death, MI, repeat PCI and CABG; 
CI confidence interval. 
 
* Number of events 
† Adjusted with propensity score as continuous variable in Cox proportional hazards model 
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Table 3.4 One-year cumulative incident proportion (K-M) and hazard ratios of 1-year outcome 
comparing statin use to no statin use among patients who took only beta blockers, no ACE inhibitor 
or calcium channel blockers 
 
Event N* 
Cumulative incident proportion Hazard 
Ratio† 95% CI P value No statin 
(n=189) 
Statin 
(n=913) 
Death 16 5.7% 1.4% 0.37 0.13-1.05 0.06 
MI 14 2.9% 1.7% 0.59 0.17-2.01 0.39 
Repeat PCI 87 14.1% 10.2% 0.66 0.39-1.11 0.11 
CABG 12 0.6% 1.5% 2.18 0.26-18.29 0.47 
Repeat PCI/CABG 98 14.7% 11.5% 0.71 0.43-1.17 0.18 
Death/MI 30 8.5% 3.1% 0.45 0.21-1.00 0.05 
Death/MI/CABG 40 9.0% 4.2% 0.56 0.27-1.16 0.12 
MACE    119 21.5% 13.4% 0.63 0.41-0.97 0.04 
MI indicates myocardial infarction; PCI percutaneous coronary intervention; CABG coronary artery 
bypass graft surgery; MACE major adverse cardiac event, consisted of death, MI, Repeat PCI, CABG; CI 
confidence interval. 
 
* Number of events 
† Adjusted with propensity score as continuous variable in Cox proportional hazards model. 
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Table 3.5 One-year cumulative incident proportion (K-M) and hazard ratios of 1-year outcome 
comparing statin use to no statin use among patients who took beta blockers, ACE inhibitor, but no 
calcium channel blockers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Event N* 
Cumulative incident 
proportion Hazard 
Ratio† 95% CI P value No statin 
(n=156) 
Statin 
(n=1198) 
Death 34 3.9% 3.5% 1.01 0.36-2.83 0.99 
MI 25 2.8% 2.1% 0.75 0.24-2.30 0.61 
Repeat PCI   115 12.5% 10.6% 0.88 0.50-1.54 0.65 
CABG 22 2.1% 1.7% 0.76 0.21-2.68 0.67 
Stent thrombosis   8 1.3% 0.6% 0.36 0.07-1.87 0.22 
Repeat 
PCI/CABG   133 14.9% 11.8% 0.80 0.48-1.35 0.41 
Death/MI 57 6.6% 5.3% 0.83 0.39-1.79 0.64 
Death/MI/CABG 73 8.0% 6.6% 0.78 0.39-1.53 0.46 
MACE   167 18.5% 15.1% 0.83 0.53-1.32 0.44 
PCI indicates percutaneous coronary intervention; CABG coronary artery bypass graft surgery; MI 
myocardial infarction; MACE major adverse cardiac event, consisted of death, MI, CABG and repeat 
PCI; CI confidence interval. 
 
* Number of events 
† Adjusted with propensity score as continuous variable in Cox proportional hazards model. 
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Table 3.6 One-year cumulative incident proportion (K-M) and hazard ratios of 1-year outcome 
comparing statin use to no statin use among patients other than in Table 3.4 and 3.5 
 
Event N* 
Cumulative incident proportion Hazard 
Ratio† 95% CI P value    No statin   
   (n=143) 
Statin 
(n=671) 
Death 24 11.2% 2.8% 0.34 0.15-0.79 0.01 
MI 23 3.7% 3.4% 0.82 0.29-2.28 0.70 
Repeat PCI 58 5.7% 9.5% 1.28 0.60-2.75 0.53 
CABG 12 2.7% 1.7% 0.87 0.18-4.18 0.86 
Repeat 
PCI/CABG 68 6.6% 11.0% 1.42 0.67-3.03 0.36 
Death/MI 44 13.5% 5.9% 0.55 0.29-1.07 0.08 
Death/MI/CABG 56 16.1% 7.6% 0.60 0.33-1.10 0.10 
MACE    101 18.5% 15.4% 0.90 0.54-1.49 0.67 
 
PCI indicates percutaneous coronary intervention; CABG coronary artery bypass graft surgery; MI 
myocardial infarction; MACE major adverse cardiac event; CI confidence interval. 
 
* Number of events 
† Adjusted with propensity score as continuous variable in Cox proportional hazards model. 
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4.1 ABSTRACT 
Background: The efficacy of treatment with multiple stents or single long stent for long lesions 
has been a topic under debate for years. It is of clinical importance to assess the effect of multiple stents 
vs. single stent among shorter lesions, because, unlike longer lesions, shorter lesions do not have to be 
treated with multiple stents.  
Methods: DEScover Registry is a prospective, multicenter, observational study between January-
June, 2005. The eligibility criteria for this analysis include: received at least one stent treatment; lesions 
were not previously treated; lesion length were 10~32mm; procedures were angiographically successful. 
Baseline characteristics, angiographic characteristics, procedural characteristics and in-hospital events 
were recorded for participating patients. Follow-up was performed at 1, 6, and 12 months by a central 
telephone facility for clinical events (death, MI, repeat PCI, CABG, stent thrombosis). For those patients 
reporting an event, a specially trained research coordinator then obtained additional information about the 
event. Adverse events, including death/MI, Repeat PCI/CABG, death/MI/CABG, death/MI/thrombosis, 
death/MI/CABG/thrombosis, were compared between patients receiving multiple stents for any lesion and 
patients receiving single long stent for every lesion. Patients with one lesion treated were analyzed 
separately from those with multiple lesions treated. 
Results: A total of 2865 patients were included in this analysis. Of these patients, 2282 patients 
had one lesion treated, and 583 patients had more than one lesion treated during the procedure. In the 
subgroup of patients with only one lesion treated, the cumulative incident proportions were higher in the 
patients who received multiple stents treatment than in those who received single stent for death/MI 
(14.8% vs. 6.4%), death/MI/CABG (15.5% vs. 7.4%), death/MI/thrombosis (15.1% vs. 6.4%), and 
death/MI/CABG/thrombosis (15.8% vs. 7.5%), lower event rate of repeat PCI/CABG (8.2% vs. 10.5%). 
In the Cox proportional hazards model, compared with the treatment with single stent, multiple stents 
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were associated with non-significantly higher risks of death/MI (HR=1.39, 95% CI: 0.80-2.41, p=0.25), 
repeat PCI/CABG (HR=1.09, 95% CI: 0.66-1.81, p=0.74), death/MI/CABG (HR=1.41, 95% CI: 0.84-
2.38, p=0.20), death/MI/thrombosis (HR=1.44, 95% CI: 0.83-2.47, p=0.19), death/MI/CABG/thrombosis 
(HR=1.45, 95% CI: 0.87-2.42, p=0.15).  
Of the 583 patients who had more than one lesion, a total of 474 (81.3%) received a single stent 
for each lesion, and 109 patients (18.7%) received multiple stents for at least one lesion. Compared to 
patients with single stents, patients with multiple stents had lower cumulative incident proportion of 
death/MI (3.0% vs. 7.8%), death/MI/CABG (5.1% vs. 9.0%), death/MI/thrombosis (3.0% vs. 7.8%), and 
death/MI/CABG/thrombosis (5.1% vs. 9.0%), and a higher cumulative incident proportion of repeat 
PCI/CABG (12.2% vs. 10.1%). The Cox proportional hazards model showed that treatment with multiple 
stents was associated with non-significantly lower risk of death/MI (HR=0.50, 95% CI: 0.11-2.24, 
p=0.37), repeat PCI/CABG (HR=0.98, 95% CI: 0.46-2.10, p=0.96), death/MI/CABG (HR=0.88, 95% CI: 
0.29-2.63, p=0.82), death/MI/thrombosis (HR=0.50, 95% CI: 0.11-2.24, p=0.37), 
death/MI/CABG/thrombosis (HR=0.88, 95% CI: 0.29-2.63, p=0.82). 
 Conclusion: Treatment with multiple stents may be associated with non-significantly higher risk 
of adverse events among patients who have one lesion, but may be associated with lower risk of adverse 
events among patients who have more than one lesion. A specifically designed study with a larger sample 
size is needed to investigate this question. 
 
Key words: Percutaneous coronary intervention, overlap, multiple stents, adverse cardiac events 
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4.2 INTRODUCTION 
In the practice of percutaneous coronary intervention (PCI), obstructive lesions that are selected for 
intervention, and are of very long length (i.e. >32mm), nearly always require the use of multiple 
overlapping stents.  In contrast, shorter lesions in the range of 10-32mm can usually be treated with either 
a single stent or multiple overlapping stents. There is contraversy as to the efficacy of treatment with 
multiple shorter stents versus a single longer stent from literature. Several investigators have reported 
similar outcomes between the 2 treatment approaches, [1-5], whereas others have reported that treatment 
with multiple stents is associated with a higher risk of adverse event rates [6-8].  
The lengths of current FDA approved stents in the US market are from 8 to 33mm.  Therefore, 
when obstructive lesions that are targeted for treatment fall within this range, the operator has a choice of 
using a single versus multiple overlapping stents.  Ultimately, full stent coverage of the lesion is the 
primary goal, while achieving this without excessive stent length in relation to lesion length.  This is 
because previous studies, particularly among bare-metal stented patients, have shown that the risk of 
restenosis is strongly associated with total stent length [9-11].  In the drug-eluting stent era, the concern 
over excessive stent length exists, but to a lesser degree compared to bare metal stents [10, 12-15].   
Finally, the use of multiple overlapping stents for lesions in the range of 10 to 32mm can occur as 
an a priori (planned) strategy by the operator, or in response to a suboptimal lesion coverage result with 
the first stent that was used.  At present, little if any data exist on evaluating the efficacy of multiple 
overlapping stents in relation to the reason in which more than one stent was used (i.e. planned approach 
versus ad hoc response in relation to suboptimal initial result).  Therefore, in this study, we investigated 
the efficacy of treatment with multiple shorter stents versus a single longer stent among lesions of 10 to 
32mm in length among patients in the DEScover Registry. 
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4.3 METHODS 
4.3.1 Study Design and Patient Population 
The DEScover Registry is a prospective, multicenter, observational study designed to characterize PCI 
patients treated from a broad sampling of hospitals and practices in the United States.  Previous details on 
the study design and patient population have been published [16, 17].  Briefly, at participating sites 
(n=140), 7,752 consecutively-enrolled patients underwent PCI between January-June, 2005.  The 
exclusion criteria were minimal: patient refusal or inability to provide written informed consent and/or 
HIPAA authorization. All interventional strategies, including the use of stents or other devices, stent(s) 
type and length, number of stents placed, and peri-procedure medications were selected at the operator’s 
discretion. The protocol was approved by a central or individual institutional review board before the 
study started. Baseline characteristics, angiographic characteristics, procedural characteristics and in-
hospital events were recorded for participating patients. Follow-up was performed at 1, 6, and 12 months 
by a central telephone facility for clinical events.  
For the present analysis, patients were included if they received at least one stent, the lesion 
treated was not previously treated (i.e. not a restenotic lesion), the lesion length was between 10 to 32mm, 
and the procedure was angiographically successful.  The latter was defined as achievement of a minimum 
stenosis diameter reduction to <50% in the presence of Thrombosis in Myocardial Infarction (TIMI) 
grade 3 flow. This resulted in an analysis cohort of 2,865 patients (37% of the total cohort).   
4.3.2 Data Management and Definitions 
Data were collected and submitted online using electronic case report forms. Password protected study 
codes were used to protect subject identity. An independent contract research organization served as 
administrator for the study, which is sponsored by Cordis, Johnson & Johnson Company (Miami Lakes, 
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Fla).  The University of Pittsburgh serves as the statistical analysis center. Follow-up was 93.2% 
complete at 6 months and 89.6% complete at 1 year.  
Complete procedural success was defined as achieving angiographic success (as defined above) 
in all attempted lesions without the occurrence of a major complication, such as myocardial infarction 
(MI), repeat revascularization during hospitalization, or death. Partial procedural success was defined as 
angiographic success in at least 1 lesion treated without an in-hospital major complication. Procedural 
failure was defined as absence of angiographic success in all lesions or occurrence of any in-hospital 
major complication. All angiographic results were reported on the basis of visual assessment by the 
individual sites (i.e. not central angiographic laboratory). 
Myocardial infarction (MI) was diagnosed by evolutionary ST-segment elevation, development 
of new Q waves or left bundle-branch block on the ECG or biochemical evidence of necrosis, including a 
total creatine kinase ≥2 times the normal upper limit with an elevated creatine kinase-MB or a positive 
troponin. Repeat PCI was categorized according to whether the index lesion (target lesion 
revascularization) or artery (target vessel revascularization) was attempted. Definite stent thrombosis was 
defined as the presence of angiographic thrombus in a stent that had been previously successfully 
deployed accompanied by an acute coronary syndrome. Angiographic thrombus was defined as complete 
occlusion with a stent diameter stenosis <30% or evidence of flow-limiting thrombus within or 
immediately adjacent to the stent. Major adverse coronary events were defined as death (all cause), MI, 
repeat PCI, or coronary artery bypass graft surgery (CABG).   
4.3.3 Statistical Methods 
Analyses were performed in subgroups of patients according to whether a single lesion (n=2282, 79.7%) 
was treated (primary analysis) or multiple lesions (n=583, 20.3%) were treated (secondary analysis).  The 
rationale for this was that the primary single lesion analysis was easiest to interpret directly in relation to 
whether a single or multiple stents were used.  In the case of multiple treated lesions, there existed the 
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possibility of a “partial” approach whereby one lesion was treated with a single stent and a second lesion 
was treated with multiple stents.  On the other hand, the secondary analysis of multiple treated lesions 
was presumably better able to judge whether multiple stents were used as a planned strategy as opposed 
to a response to complications with the initial stent.  Specifically, if a patient had multiple lesions treated 
with multiple stents for each lesion, one can infer that this was likely the planned approach rather than a 
response to suboptimal initial stent result. 
For both subgroups, patients were categorized into 2 groups according to whether a single or 
multiple stents were used to treat a lesion.  Differences in continuous variables were compared by student 
t-tests. Differences in proportions of categorical variables were compared by chi-square tests.  The 
Kaplan-Meier method was used to estimate cumulative incident proportion of each adverse event in each 
group. Patients were censored at the last known date of contact or after the first occurrence of the event of 
interest.  For each subgroup, a separate propensity score model was fit by use of logistic regression to 
adjust for the potential selection bias inherent in the decision to dilate the lesion(s) with multiple shorter 
stents versus a single longer stent [18-24]. A candidate list of baseline variables were included in the 
propensity score model (refer to Appendix B). A backward selection method was used with a p value of 
0.40 to select variables.  If balance was not achieved for certain covariates, the propensity model will be 
refitted by including these covariates in the model. Cox proportional hazards regression was used to 
estimate the independent effect of the use of multiple overlapping stents versus a single stent on the 
relative hazard of adverse clinical outcomes.  The propensity score was the single covariate that was 
included in the model to control for confounding in addition to the binary exposure variable of single 
versus multiple overlapping stents.  The proportional hazards assumption of constant relative risk over 
follow-up was evaluated by testing the interaction between time and the primary exposure (multiple 
stents/single stent).  All statistical analyses were performed using the SAS program, version.9.1 (SAS 
Institute, Cary, NC).  
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4.4 RESULTS 
Between January and June 2005, 7752 patients were enrolled in DEScover Registry. A total of 2865 
patients were eligible in this analysis. Of these patients, 2282 patients had one lesion treated, and 583 
patients had more than one lesion treated during the procedure.  The proportional hazards assumption of 
constant relative risk over follow-up was found to be upheld.  The analysis results for the two subgroups 
are shown below.  
4.4.1 PATIENTS WHO HAVE ONLY ONE LESION 
Among the 2282 patients who have only one lesion, a total of 2002 (87.7%) patients received single stent, 
and 280 (12.3%) patients receive more than one stent. The median follow up time is 12 month. The 
median follow-up time among patients who did not have any adverse event is 12 month. Table 4.1 shows 
the patient demographics, disease history and angiographic characteristics in each treatment group. The 
practice of single stent or multiple stents differed among regions of US. Patients from North East or West 
were more likely to receive multiple stents treatment, while patients from South East and South West 
were more likely to receive single stent treatment. No significant difference was found between the two 
treatment groups in terms of other patient demographics, disease history, and angiographic characteristics 
(Table 4.1). After propensity score adjustment, none of the differences was statistically significant.  
The primary reason for revascularization and circumstance of procedure was similar between the 
two treatment groups (Table 4.2). However, patients who received multiple stents tended to have longer 
lesion than patients who received a single stent (mean length, 22.0 mm vs. 17.7 mm, p<0.01). The 
proportion of occlusion was higher among patients who received multiple stents than among patients who 
received single stent (16.4% vs. 10.7%, p=0.01). After propensity score adjustment, none of these 
differences was statistically significant.  
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The variables to predict the propensity score from the logistic model are shown in Appendix B. 
The c statistic for the propensity score model was 0.74, indicating a probability of 0.74 that for a 
randomly selected subject receiving multiple stents the propensity score would be higher than for a 
randomly selected subject receiving single stent. Patients treated with multiple stents had higher average 
propensity score than patients treated with one stent (0.21 vs. 0.11). The distribution of propensity scores 
among patients treated with one stent and patients treated with multiple stents is shown in Figure 4.1.  
 
Figure 4.1 Boxplot of propensity score between patients treated with one stent and patients treated  
with multiple stents (primary analysis)* 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower quartile (Q1, X .25),  
             median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher than Q3. The two  
whiskers below and above the shaded box indicate the smallest and largest values that are not  
outliers. 
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 Cumulative incident proportions estimated with Kaplan-Meier method are shown in Table 4.3. 
The cumulative incident proportions were higher in the group treated with multiple stents than in the 
group treated with single stent for death/MI (14.8% vs. 6.4%), death/MI/CABG (15.5% vs. 7.4%), 
death/MI/thrombosis (15.1% vs. 6.4%), and death/MI/CABG/thrombosis (15.8% vs. 7.5%), lower 
cumulative incident proportions of repeat PCI/CABG (8.2% vs. 10.5%). In Cox proportional hazards 
model, compared with the treatment with single stent, multiple stents were non-significantly associated 
with higher risk for death/MI (HR=1.39, 95% CI: 0.80-2.41, p=0.25), repeat PCI/CABG (HR=1.09, 95% 
CI: 0.66-1.81, p=0.74), death/MI/CABG (HR=1.41, 95% CI: 0.84-2.38, p=0.20), death/MI/thrombosis 
(HR=1.44, 95% CI: 0.83-2.47, p=0.19), death/MI/CABG/thrombosis (HR=1.45, 95% CI: 0.87-2.42, 
p=0.15) (Table 4.3). 
4.4.2 PATIENTS WHO HAVE MORE THAN ONE LESION 
Of the 583 patients who had more than one lesion, a total of 474 patients (81.3%) received single stent for 
each lesion, and 109 patients (18.7%) received multiple stents for at least one lesion. Among all patients 
the median follow up is 12 months. Among patiens without any adverse events the median follow up is 12 
months. 
Patient demographics, disease history, and angiographic characteristics are shown for each 
treatment group in Table 4.4. Patients who received multiple stents were more likely to be female (37.6% 
vs. 28.5%), less likely to have hypercholesterolemia (71.0% vs. 81.2%), history of hypertension (70.1% 
vs. 78.6%), or history of prior intervention (22.6% vs. 31.2%). The choice of treatment with single stent 
or multiple stents was different among different regions of US. Patients from North East were more likely 
to receive multiple stents for their lesions than patients in other region, and patients from South East and 
South West were more likely to receive single stent for their lesions than patients in other region. No 
significant differences were found between the two treatment in terms of other demographic 
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characteristics, disease history and angiographic characteristics. After propensity score adjustment, none 
of the differences was statistically significant.  
The primary reason for revascularization and circumstance of procedure were similar among the 
two groups (Table 4.5). Patients receiving multiple stents were more likely to have lesion calcification 
(78.0% vs. 69.2%, p=0.07). No significant differences were found between the two treatments in terms of 
other lesion characteristics. After propensity score adjustment, none of the differences was statistically 
significant.  
The variables to predict the propensity score from the logistic model are shown in Appendix B. 
The c statistic of the propensity model was 0.76, indicating a probability of 0.76 that for a randomly 
selected subject receiving multiple stents the propensity score would be higher than for a randomly 
selected subject receiving single stent. Patients treated with multiple stents had higher average propensity 
score than patients treated with one stent (0.29 vs. 0.15). The distribution of propensity scores among 
patients treated with one stent and patients treated with multiple stents is shown in Figure 4.2. 
Cumulative incident proportion of adverse even estimated with Kaplan-Meier method is shown in 
Table 4.6. These are defined as 1- estimated probablity of no adverse events. The cumulative incident 
proportions were lower in the group of multiple stents treatment than in the group of single stent in terms 
of death/MI (3.0% vs. 7.8%), death/MI/CABG (5.1% vs. 9.0%), death/MI/thrombosis (3.0% vs. 7.8%), 
and death/MI/CABG/thrombosis (5.1% vs. 9.0%), higher cumulative incident proportion of repeat 
PCI/CABG (12.2% vs. 10.1%).  
In the Cox proportional hazards model, compared with the treatment with single stent, multiple 
stents were associated with a non-significantly lower risk of death/MI (HR=0.50, 95% CI: 0.11-2.24, 
p=0.37), Repeat PCI/CABG (HR=0.98, 95% CI: 0.46-2.10, p=0.96), death/MI/CABG (HR=0.88, 95% CI: 
0.29-2.63, p=0.82), death/MI/thrombosis (HR=0.50, 95% CI: 0.11-2.24, p=0.37), 
death/MI/CABG/thrombosis (HR=0.88, 95% CI: 0.29-2.63, p=0.82) (Table 4.6).  
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 Figure 4.2 Boxplot of propensity score between patients treated with one stent and patients treated  
with multiple stents (secondary analysis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower 
            quartile (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher  
than Q3. The two whiskers below and above the shaded box indicate the smallest  
and largest values that are not outliers. 
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4.5 DISCUSSION 
The present study demonstrates that among patients with one lesion treated treatment with multiple stents 
for lesions of 10~32mm was associated with non-significantly increased risk of death/MI, repeat 
PCI/CABG, death/MI/CABG, death/MI/thrombosis, and death/MI/CABG/thrombosis when compared 
with treatment with single stent. For patients with more than one lesion treated, treatment with multiple 
stents was associated with non-significantly reduced risk of adverse clinical outcome when compared to 
treatment with single stent.   
The use of multiple stents per lesion has been a subject under debate for a long time[1, 4, 8, 15, 
25]. However, interventional cardiologists sometimes can not avoid multiple stenting in a long lesion. The 
stent lengths are 8~33mm at current US market, although stents of longer length can be obtained under 
specific request. Therefore, to investigate the efficacy of multiple stents per lesion vs. single long stent 
among lesions of 10-32 mm in length not only complements to the investigation of long lesions, but also 
is of clinical importance. 
In our study we found treatment with multiple stents was non-significantly associated with higher 
risk of adverse events among patients with one lesion treated. Previous studies have also reported an 
adverse effect of multiple stents treatment [6-8, 25]. Some researchers believed the overlapped stent strut 
served as a stimulus to neointimal hyperplasia [7, 26-28]. A recent study by Kereiakes et al. showed that 
stent overlap was associated with neointimal proliferation and subsequent late lumen loss regardless of 
bare metal stent (BMS) or sirolimus-eluting stent (SES) [1]. For drug-eluting stent (DES), the relative 
importance of stimulus from overlapped stent metal versus the efficacy of stent-based drug to suppress 
neointimal growth has been under discussion [29]. Kereiakes et al. found that the relative magnitude of 
restenosis reduction observed in patients treated with single SES versus BMS was maintained in the 
comparison of patients treated with overlapped SES versus treated with overlapped BMS, indicating 
sirolimus is effective in reducing high degree of neointimal proliferation and late lumen loss observed in 
overlapped stents [1]. However, TAXUS-V and VI trials reported a higher incidence of periprocedural 
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myocardial enzyme elevation among patients treated with overlapped paclitaxel-eluting stent (PES) when 
compared to patients receiving overlapped EXPRESS stent [12]. The metal platforms are similar between 
PES and EXPRESS. The difference in the incidence of MI can be related to the polymer and 
pharmacologic agent on the stent, although a post-hoc angiographic analysis suggested that the reduction 
in side branch flow in patients treated with overlapped PES could be the reason [30]. Studies also showed 
that multiple stent per lesion is an independent predictor for stent thrombosis, regardless of BMS or DES 
[31, 32]. Although stent thrombosis is a rare event, the mortality rate is about 40% and MI rate is very 
high among survivors.  
We found a beneficial effect of treatment with multiple stents compared to single stent among 
patients having more than one lesion. Several other studies had similar findings. Kereiakes et al. reported 
that overlapping of multiple SES per lesion is both safe and efficacious in reducing restenosis [1]. Chu et 
al. also reported that overlapping of SES is feasible and effective for long, native coronary lesions, 
although it is associated with an increased rate of periprocedural myonecrosis [2]. Kornowski et al. 
reported that patients treated with multiple stents per lesion had similar target lesion revascularization 
(TLR) rate and major cardiac event rate (MACE) at one-year follow-up[4]. Hoffmann et al. reported a 
similar angiographic restenosis rate between treatments with two stents vs. single long stent in long lesion 
[3]. Pan et al. reported a similar survival at follow-up for multiple stenting and single long stent [5]. Lee 
et al. reported a similar rate of in-stent restenosis (ISR) between overlapping of multiple stents vs. one 
long stent in long tortuous or calcified lesions (>20 mm) and long lesions with diameter discrepancy or 
significant dissection (> 20mm) [33].  
Although we do not know the biological reason why patients with one lesion react differently 
from patients who have more than one lesion, one possible reason could be the treatment strategy. The 
strategy of treatment with multiple stents can be an a priori strategy or can be a measure taken to meet the 
requirements of unanticipated complications. The complications during procedure include dissection, side 
branch occlusion, persistent flow reduction, abrupt closure, device malfunction, or others complications. 
It is reported that up to one-third or more of coronary stent procedures may be complicated by excessive 
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target lesion length, incomplete target lesion coverage, or stent marginal dissection, which may require 
multiple stents for full lesion coverage [34-37]. When additional stents are required by the difficult 
situations during procedure, the adverse effect of treatment with multiple stents we observed here may 
only be a proxy of the difficult procedural situations. The more it occurred among the patients with one 
lesion, the higher adverse effect of multiple stent treatment we expect to observe. On the other hand, the 
beneficial effect of treatment with multiple stents among patients with more than one lesion is not 
conclusive. Although our results suggested a trend of benefit for each adverse event, the associations are 
not statistically significant. The sample size and number of events are low in this subgroup.  
Our study has its limitations despite prospective study design and detailed information about 
demographic, procedure, lesion characteristics and high follow-up rate. First, our study is lack of 
randomization, which makes our conclusion susceptible to unknown factors. Second, we do not know 
whether the treatment strategy of multiple stents is an a priori plan or it is only a measure to account for 
the unanticipated procedure complications or other difficult circumstance. Third, the sample size is not 
large enough for each adverse event. The number of patients with more than one lesion is especially low. 
A specifically designed study with larger sample size is needed to investigate the question.  
4.6 CONCLUSIONS 
Treatment with multiple stents may be associated with non-significantly higher risk of adverse events 
among patients who have one lesion, but may be associated with lower risk of adverse events among 
patients who have more than one lesion. Further specifically designed study with larger sample size is 
needed to investigate this topic. 
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Table 4.1 Patient demographics, disease history, and angiographic characteristics among patients 
having one lesion treated 
 
Characteristics single stent (n=2002) 
Multiple stents 
(n=280) P value† P value‡ 
Female, % 31.6 31.1 0.87 0.99 
Age in year             63.7(11.5)        63.6(11.8) 0.88 0.59 
Insurance 
   Medicare 
   Medicaid 
   Private Insurance 
   No insurance 
 
42.3 
4.0 
50.0 
3.7 
 
43.5 
4.8 
47.6 
4.1 
 
0.83 
 
0.74 
Region 
   Middle West 
   North East 
   South East 
   South West 
   West 
 
27.7 
30.4 
25.9 
7.3 
8.7 
 
26.4 
36.4 
20.7 
5.4 
11.1 
 
0.08 
 
0.99 
Prior intervention, % 33.3 32.4 0.76 0.98 
Prior CABG 17.4 21.0 0.15 0.36 
Prior MI 24.7 27.9 0.25 0.96 
Severe non-cardiac disease 32.3 34.3 0.51 0.29 
History of diabetes 31.1 31.5 0.88 0.99 
History of CHF 10.1 12.5 0.23 0.56 
History of hypertension 73.9 74.9 0.73 0.89 
History of 
hypercholesterolemia 
 
74.3 
 
74.1 
 
0.93 
 
0.69 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 4.2 Procedure and lesion characteristics among patients having one lesion treated 
 
Characteristics single stent (n=2002) 
Multiple stents 
(n=280) P value† P value‡ 
Cause of procedure 
    Acute MI w/o shock 
    Acute MI with shock 
    Unstable angina 
    Stable angina 
    Positive for ischemia study 
    Other 
    Unknown  
 
21.5 
1.3 
29.3 
15.1 
24.2 
7.9 
0.6 
 
23.2 
1.4 
27.5 
11.1 
25.0 
11.1 
0.7 
 
0.38 
 
0.21 
Procedure circumstance 
    Elective 
    Urgent 
    Emergent  
 
63.9 
24.9 
11.2 
 
65.7 
22.5 
11.8 
 
0.67 
 
0.88 
Lesion length, mm       17.7(4.9)    22.0(5.7)    <0.01 0.65 
Occlusion 10.7 16.4 0.01 0.86 
Calcification 69.2 70.7 0.61 0.97 
Ostial lesion 6.1 5.7 0.80 0.59 
MI indicated myocardial infarction. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 4.3 Cumulative incident proportions of adverse events and hazard ratios comparing multiple 
stents use to single long stent use among patients having only one lesion treated 
 
 Event 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 
 
95% CI p value    Single stent
   (n=2002) 
Multiple stents 
(n=280) 
Death/MI 6.4% 14.8% 1.47 1.39 0.80-2.41 0.25 
Repeat PCI/CABG 10.5% 8.2% 0.99 1.09 0.66-1.81 0.74 
Death/MI/CABG 7.4% 15.5% 1.43 1.41 0.84-2.38 0.20 
Death/MI/thrombosis 6.4% 15.1% 1.53 1.44 0.83-2.47 0.19 
Death/MI/CABG/thrombosis  7.5% 15.8% 1.48 1.45 0.87-2.42 0.15 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention.  
 
† Crude hazard ratio without adjustment with propensity score in Cox model. 
‡ Adjusted hazard ratio with propensity score as continuous variable in Cox model. 
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Table 4.4 Patient demographics, disease history, and angiographic characteristics among 
patients who have more than one lesion treated 
  
Characteristics All single stent (n=474) 
Multiple stent  
(n=109) P value† P value‡ 
Female, % 28.5 37.6 0.06 0.87 
Age in year            64.9(11.0)          64.4(12.5) 0.63 0.90 
Insurance 
    Medicare 
    Medicaid 
    Private Insurance 
    No insurance 
 
45.8 
2.5 
47.5 
4.2 
 
41.2 
1.0 
54.9 
2.9 
 
0.49 
 
0.57 
Region 
    Middle West 
    North East 
    South East 
    South West 
    West 
 
26.6 
24.9 
31.2 
7.4 
9.9 
 
27.5 
38.5 
22.0 
3.7 
8.3 
 
0.04 
 
0.99 
Prior intervention, % 31.2 22.6 0.08 0.97 
Prior CABG 17.6 17.9 0.93 0.84 
Prior MI 26.6 29.3 0.58 0.95 
Severe non-cardiac disease 35.3 32.1 0.52 0.99 
History of diabetes 35.0 41.9 0.18 0.87 
History of CHF 11.6 13.2 0.63 0.77 
History of hypertension 78.6 70.1 0.06 0.97 
History of hypercholesterolemia 81.2 71.0 0.02 0.34 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 4.5 Procedure and lesion characteristics among patients who have more than one lesion 
treated 
 
Characteristics single stent (n=474) 
Multiple stent  
(n=109) P value† P value‡ 
Cause for procedure 
    Acute MI  
    Unstable angina 
    Stable angina 
    Positive for ischemia study 
    Other 
 
22.6 
31.2 
15.8 
22.4 
8.0 
 
16.5 
33.0 
15.6 
21.1 
13.8 
 
0.31 
 
0.99 
Procedure circumstance 
    Elective 
    Urgent 
    Emergent  
 
64.8 
26.2 
9.1 
 
72.5 
22.0 
5.5 
 
0.26 
 
0.90 
More than two lesions 13.9 16.5 0.49 0.97 
Any occlusion 8.4 5.5 0.31 0.24 
Any calcification 69.2 78.0 0.07 0.86 
Any ostial lesion 8.0 11.0 0.32 0.26 
MI indicates myocardial infarction. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 4.6 Cumulative incident proportions of adverse events and hazard ratios comparing multiple 
stents use to single long stent use among patients having more than one lesion treated 
 
 Event 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 
 
95% CI p value Single stent 
(n=474) 
multiple stents 
(n=109) 
Death/MI 7.8% 3.0% 0.48 0.50 0.11-2.24 0.37 
Repeat PCI/CABG 10.1% 12.2% 1.24 0.98 0.46-2.10 0.96 
Death/MI/CABG 9.0% 5.1% 0.67 0.88 0.29-2.63 0.82 
Death/MI/thromb 7.8% 3.0% 0.48 0.50 0.11-2.24 0.37 
Death/MI/CABG/thrombosis 9.0% 5.1% 0.67 0.88 0.29-2.63 0.82 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention; CI confidence interval.  
 
† Crude hazard ratio without adjustment with propensity score in Cox model. 
‡ Adjusted hazard ratio with propensity score as continuous variable in Cox model. 
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5.1 ABSTRACT 
Background: In percutaneous coronary intervention (PCI), postdilation effectively increases stent 
dimension. Evidence regarding the long-term efficacy of routine stent postdilation on clinical outcomes is 
limited, particularly among different patient subgroups.  
Methods: Patients were evaluated from the multi-center National Heart, Lung, and Blood Institute 
(NHLBI) Dynamic registry recruitment Wave 4 (2004) and Wave 5 (2006) cohorts.   Patient eligibility 
criteria for this analysis included receipt of >1 stent treatment and an angiographically successful PCI 
procedure. The analysis was conducted among two subgroups: patient presenting with (N=938) and 
without (N=2264) acute myocardial infarction (AMI). Among each of the two subgroups, analyses were 
carried out separately for patients having one lesion treated (N=1629 for patients without AMI, N=713 for 
acute MI patients) and patients having more than one lesion treated (N=635 for patients without AMI, 
N=225 for acute MI patients). Baseline, procedure, and lesion information were collected. Adverse 
cardiac events were compared at one-year follow up by the performance or absence of lesion postdilation. 
Results: Among patients without AMI with one lesion treated, postdilation was not associated 
with adverse cardiac events, although some, but not all, risk estimates were in the direction of a protective 
effect: death (adjusted HR, 0.81; 95% CI, 0.40-1.59; P=.54), repeat PCI (adjusted HR, 0.87; 95% CI, 
0.57-1.33; P=.52), death/MI (adjusted HR, 0.90; 95% CI, 0.56-1.45; P=.67), MACE (adjusted HR, 0.89; 
95% CI, 0.65-1.22; P=.46). Similarly, postdilation among patients without AMI with >1 lesion was not 
associated with adverse cardiac events: death/MI (adjusted HR, 0.81; 95% CI, 0.36-1.81; P=.60), repeat 
PCI/CABG (adjusted HR, 1.39; 95% CI, 0.82-2.38; P=.22), MACE (adjusted HR, 1.45; 95% CI, 0.91-
2.30; P=.12). 
Among acute MI patients with one lesion treated, postdilation was associated with a significantly 
higher risk of death (adjusted HR, 3.46; 95% CI, 1.09-11.03; P=.04). No association was observed for risk 
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of repeat procedures. Among acute MI patients with >1 lesion treated, postdilation was not associated 
with death/MI (adjusted HR, 0.79; 95% CI, 0.23-2.73; P=.71), repeat PCI/CABG (adjusted HR, 0.99; 
95% CI, 0.36-2.73; P=.98), or MACE (adjusted HR, 0.79; 95% CI, 0.34-1.82; P=.57). 
Conclusion: Among PCI patients presenting with acute MI, postdilation is associated with 
significantly increase the risk of death at 1-year.  However, this finding was observed only among patents 
with one lesion treated and not among patients with multiple lesions treated and may be spurious.  Among 
non-acute MI PCI patients, lesion postdilation does not appear to be associated with trend towards 
benefit.  Further investigation is needed to determine whether a strategy of postdilation among acute MI 
patients should be discouraged.  
 
Key words: Percutaneous coronary intervention, postdilation, acute MI, adverse cardiac events, 
stent 
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5.2 INTRODUCTION 
In early-era balloon-expandable stents were delivered with compliant balloons. Postdilation with 
noncompliant balloons at higher pressure is performed to optimize stent deployment. This results in less 
acute complications and lower rate of restenosis. Recent stent delivery systems use semicompliant 
balloons to deploy stents at higher pressure, initially leading to less postdilation after stent deployment. 
However, studies with intravascular ultrasound (IVUS) showed that only few patients achieved optimal 
stent expansion with the current stent delivery system [1-3].  
Although postdilation with noncompliant balloon increases stent dimensions in the short term [2], 
there is little evidence about its long term effect on clinical outcomes, especially among Acute MI (AMI) 
patients who are at higher risk of distal embolization [4-6]. In this study we will assess whether 
postdilation results in better patient outcomes at one-year follow-up among patients without Acute MI and 
patients with Acute MI.  
5.3 METHODS 
5.3.1     Patient Selection and Data Collection 
The National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry includes 14 clinical sites in 
Wave 4, and 16 clinical sites in Wave 5 as well as a data coordinating center at University of Pittsburgh. 
Wave 4 began in 2004, consecutively recruited 2112 patients. Wave 5 began in 2006, consecutively 
recruited 2158 patients. Consecutive enrollment at each site ended when 125 white men had been enrolled 
at the site or 1,600 white patients were enrolled across all sites. Consecutive enrollment of women and 
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minorities continued at each site until 200 white patients had been enrolled at the site or 1,600 white 
patients were enrolled across all sites. Consecutive enrollment of minority patients, men and women, 
continued until 2,000 patients had been enrolled across all sites. Informed consent was obtained. On-site 
research coordinators were trained before the wave started. Standard forms were used to collect data. For 
present analysis, patients were included if they received at least one stent, received balloon predilation 
before stent implantation, and the procedure was angiographically successful. The latter was defined as 
achievement of a minimum stenosis diameter reduction to <50% in the presence of Thrombosis in 
Myocardial Infarction (TIMI) grade 3 flow. This resulted in an analysis cohort of 3202 patients.   
Successful lesion dilation was defined as an absolute reduction of at least 20% in lesion severity 
and a final stenosis of <50% (diameter reduction). Partial angiographic success was defined as some but 
not all lesions were successfully treated; total angiographic success was defined as all attempted lesions 
were treated successfully. Procedural success was defined as partial or total angiographic success without 
in-hospital death, myocardial infarction, or emergency coronary artery bypass graft surgery. Myocardial 
infarction (MI) was defined by evidence of ≥2 of the following: (1) typical chest pain > 20 minutes, not 
relieved by nitroglycerin; (2) serial electrocardiograms showing characteristic ST-T changes and/or Q 
waves in ≥2 contiguous leads; (3) serial electrocardiograms showing characteristic ST-T changes and/or 
Q waves in ≥2 contiguous leads; (4) serum enzyme elevation of creatine kinase-MB is more than 5% of 
total creatine kinase. 
5.3.2    Statistical Methods 
Analyses in each subgroup were carried out separately among patients with one lesion treated (primary 
analysis) and among patients with >1 lesion treated (secondary analysis).  The rationale for this was that 
the primary single lesion analysis was easiest to interpret directly in relation to whether postdilation was 
used.  In the case of multiple treated lesions, a “partial” approach is possible, whereby one lesion was 
postdilated and a second lesion was not postdilated. 
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For both subgroups, patients were categorized into 2 groups according to whether postdilation 
was performed. Differences in continuous variables were compared using t-test. Differences in 
proportions of categorical variables were compared by chi-square tests.  One-year cumulative incident 
proportion in each group was estimated with Kaplan-Meier method.  Patients were censored at one-year 
follow-up. For each subgroup, a propensity score model was fit by use of logistic regression to adjust for 
the potential selection bias inherent in the decision to postdilate the stent versus not [7-12]. A backward 
selection method was used with a p value of 0.40 to select variables for the prediction of propensity score. 
If balance was not achieved for certain covariates, the propensity model will be refitted by including these 
covariates in the model. Cox proportional hazards regression was used to estimate the independent effect 
of the use of postdilation versus not postdilation on the relative hazard of adverse clinical outcomes over 
1-year follow-up.  The propensity score was the single covariate that was included in the model to control 
for factors associated with postdilation. The binary exposure variable was postdilation versus not 
postdilation.  The proportional hazards assumption of constant relative risk over follow-up was evaluated 
by evaluating the exposure by time interaction.  All statistical analyses were performed using the SAS 
program, version.9.1 (SAS Institute, Cary, NC). 
5.4 RESULTS 
A total of 3202 patients were included in the analysis. Among these, 2264 patients (71%) did not have 
Acute MI (AMI), and 938 patients (29%) had Acute MI. The proportional hazards assumption of constant 
relative risk over follow-up was evaluated and found to be upheld.  Results are shown separately for each 
of the two subgroups. 
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5.4.1 PATIENTS WITHOUT ACUTE MI 
PATIENTS WITH ONE LESION TREATED 
Among the total 1629 Patients without AMI who had one lesion treated, 1037 patients (64%) did not 
received postdilation, and 592 patients (36%) received postdilation. The median follow up was 7 months 
and 77% of patients had at least 6-month follow up.  
The patient demographics, disease history and angiographic characteristics are shown in Table 
5.1 for two treatment groups. Patients who received postdilation were less likely to have history of CHF 
(8.2% vs. 11.6%), more likely to be amenable with Coronary Artery Bypass Grafting surgery according to 
the clinician (78.4%% vs. 71.1%), more likely to be hispanice (6.1% vs. 3.3%), to have private insurance 
or none insurance (49.8% vs. 43.8% for private insurance, 2.0% vs. 0.9% for none insurance). After 
propensity score adjustment, none of these differences were statistically significant.  
Procedure and lesion characteristics are shown in Table 5.2. Patients who received postdilation 
were more likely to receive PCI at the same setting as diagnostic catheterization (79.4% vs. 73.3%, 
p<0.01). Patients receiving postdilation were more likely to have, on average, longer lesions (19.1 vs. 
15.3 mm, p<0.01), calcified lesions (38.0% vs. 25.8%, p<0.01), ulcerated lesions (13.3% vs. 9.9%, 
p=0.04), C type of ACC/AHA classification (31.9% vs. 19.0%, p<0.01). After propensity score 
adjustment, none of these differences were statistically significant.  
The variables to predict the propensity score from the logistic model are shown in Appendix C. 
The c statistic of the propensity score model was 0.72, indicating a probability of 0.72 that for a randomly 
selected subject receiving postdilation the propensity score would be higher than for a randomly selected 
subject not receiving postdilation. The mean propensity score in the postdilation groups was higher than 
in the no postdilation group. The distribution of propensity score in the two treatment groups are shown in 
Figure 5.1. 
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 Figure 5.1 Boxplot of propensity scores between two treatment groups among patients  
without acute MI who had one lesion treated 
 
 
 
 
 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower 
            quartile (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher  
than Q3. The two whiskers below and above the shaded box indicate the smallest  
and largest values that are not outliers. 
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Compared to patients who did not receive postdilation, patients receiving postdilation had non-
significantly lower cumulative incident proportion of death, repeat PCI, repeat PCI/CABG, death/MI, 
death/MI/CABG, MACE, non-significantly higher event rate of MI and CABG (Table 5.3). The hazard 
ratios from Cox proportional hazards model for each event were all below 1.0 (Death, HR=0.81; repeat 
PCI, HR=0.87; repeat PCI/CABG, HR=0.95; death/MI, HR=0.90; death/MI/CABG, HR=0.97; MACE, 
HR=0.89), except a higher risk for CABG (HR=2.23, 95% CI: 0.84-5.96, p=0.11) and a slightly higher 
hazard ratio for MI (HR=1.27, 95% CI: 0.68-2.36, p=0.45). None of these hazard ratios is statistically 
significant.  
5.4.2 PATIENTS WITHOUT ACUTE MI 
PATIENTS WITH MORE THAN ONE LESION TREATED 
Among 643 Patients without AMI who have more than one lesion treated, 335 patients (53%) did not 
receive postdilation, and 300 patients (47%) received postdilation. The median follow up was 7 months 
and 77% of patients had at least 6-month follow up.  
Patient’s demographics, disease history, and angiographic characteristics are shown in Table 5.4. 
Patients who received postdilation were less likely to have history of CABG (16.3% vs. 23.5%), history 
of hypertension (79.6% vs. 85.6%), be amenable with PCI (87.3% vs. 92.0%). After propensity score 
adjustment, none of these differences were statistically significant. 
Procedure and lesion characteristics are shown in Table 5.5. Patients who received postdilation 
were more likely to have PCI procedure at the same setting as diagnostic setting (69.7% vs. 62.2%). After 
propensity score adjustment, this difference was not statistically significant. 
The variables to predict the propensity score from the logistic model are shown in Appendix C. 
The c statistic of the propensity score model was 0.73, indicating a probability of 0.73 that for a randomly 
selected subject receiving postdilation the propensity score would be higher than for a randomly selected 
subject not receiving postdilation. The mean propensity score in the postdilation groups was higher than 
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in the no postdilation group. The distribution of propensity score in the two treatment groups are shown in 
Figure 5.2. 
 
 
 
 
 
Figure 5.2 Boxplot of propensity scores between two treatment groups among patients  
without acute MI who had more than one lesion treated 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower 
            quartile (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher  
than Q3. The two whiskers below and above the shaded box indicate the smallest  
and largest values that are not outliers. 
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One-year cumulative incident proportion estimated with Kaplan-Meier method are shown in 
Table 5.6. Compared to patients who did not receive postdilation, patients who received postdilation had 
non-significantly lower cumulative incident proportion of death/MI (5.0% vs. 7.2%), and non-
significantly higher cumulative incident proportion of Repeat PCI/CABG (14.9% vs. 12.0%) and 
death/MI/CABG/thrombosis (20.0% vs. 16.0%). Crude and adjusted hazard ratios from Cox proportional 
hazards model are shown in Table 5.7. Postdilation was not significantly associated with death/MI 
(HR=0.81, 95% CI: 0.36-1.81, p=0.60), repeat PCI/CABG (HR=1.39, 95% CI: 0.82-2.38, p=0.22), or 
death/MI/CABG/thrombosis (HR=1.45, 95% CI: 0.94-2.30, p=0.12). 
5.4.3 ACUTE MI PATIENTS 
PATIENTS WITH ONE LESION TREATED 
Among the total 713 Acute MI patients with one lesion treated, 445 patients (62%) did not received 
postdilation, and 268 patients (38%) received postdilation. The median follow up was 7 months and 74% 
of patients had at least 6-month follow up.  
Patient demographics, disease history, and angiographic characteristics are shown in table 5.7. 
Patients who receive postdilation were more likely to be Hispanic (7.5% vs. 3.2%), more likely to be right 
dominance (88.9% vs. 80.4%). After propensity score adjustment, these differences were not statistically 
significant. 
Procedure and lesion characteristics are shown in Table 5.8. Patients who received postdilation 
were more likely to have, on average, longer lesions (20.4 vs. 15.8 mm, p<0.01), ulcerated lesion (30.2% 
vs. 23.2%, p=0.04), ostial lesion (8.2% vs. 4.0%, p=0.02), C type of lesion (36.9% vs. 28.1%, p=0.01). 
After propensity score adjustment, none of these differences was statistically significant.  
The variables to predict the propensity score from the logistic model are shown in Appendix C. 
The c statistic of the propensity score model was 0.78, indicating a probability of 0.78 that for a randomly 
selected subject receiving postdilation the propensity score would be higher than for a randomly selected 
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subject not receiving postdilation. The mean propensity score in the postdilation groups was higher than 
in the no postdilation group. The distribution of propensity score in the two treatment groups are shown in 
Figure 5.3. 
 
Figure 5.3 Boxplot of propensity scores between two treatment groups among patients with  
acute MI who had one lesion treated 
 
 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower 
            quartile (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher  
than Q3. The two whiskers below and above the shaded box indicate the smallest  
and largest values that are not outliers. 
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One-year cumulative incident proportion estimated with Kaplan-Meier method are shown in 
Table 5.9. Compared to patients who did not receive postdilation, patients who received postdilation had 
higher event rates for each adverse event. After adjustment in Cox proportional hazards model, a 
significantly higher risk of death was observed (HR=3.46, 95% CI: 1.09-11.03, p=0.04) among patients 
who received postdilation when compared to patients who did not, non-significant higher risks of all the 
other adverse events also were observed among patients who received postdilation than among patients 
who did not.  
5.4.4 ACUTE MI PATIENTS 
PATIENTS WITH MORE THAN ONE LESION TREATED 
Among 225 Acute MI patients who have more than one lesion, 113 patients (50%) did not receive 
postdilation, 112 patients (50%) received postdilation. The median follow up was 7 months and 77% of 
patients had at least 6-month follow up.  
Patient’s demographics, disease history, and angiographic characteristics are shown in Table 
5.10. Patients who received postdilation were more likely to have history of MI (30.4% vs. 17.3%). After 
propensity score adjustment, this difference was not statistically significant. 
Procedure and lesion characteristics are shown in Table 5.11. Patients who received postdilation 
were more likely to have PCI procedure at the same setting as diagnostic catheterization (88.6% vs. 
79.0%). After propensity score adjustment, no comparisons were statistically significant. 
The variables to predict the propensity score from the logistic model are shown in Appendix C. 
The c statistic of the propensity score model was 0.85, indicating a probability of 0.85 that for a randomly 
selected subject receiving postdilation the propensity score would be higher than for a randomly selected 
subject not receiving postdilation. The mean propensity score in the postdilation groups was higher than 
in the no postdilation group. The distribution of propensity score in the two treatment groups are shown in 
Figure 5.4. 
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Figure 5.4 Boxplot of propensity scores between two treatment groups among patients with  
acute MI who had more than one lesion treated 
 
 
 
 
 
 
 
 
 
 
*  The three horizontal lines in the shaded box from bottom to top stand for lower 
            quartile (Q1, X .25), median (med, X .5), upper quartile (Q3, X .75), respectively.  
            Interquartile range (IQR) is defined as Q3-Q1. 
 
Outliers are values which lie more than 1.5*IQR lower than Q1 or 1.5*IQR higher  
than Q3. The two whiskers below and above the shaded box indicate the smallest  
and largest values that are not outliers. 
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One-year cumulative incident proportions estimated with Kaplan-Meier method are shown in 
Table 5.12. Compared to patients who did not receive postdilation, patients who received postdilation had 
non-significantly higher cumulative incident proportion of death/MI (9.2% vs. 7.8%), 
death/MI/CABG/thrombosis (20.9% vs. 18.0%), and almost same cumulative incident proportion of 
repeat PCI/CABG (13.5% vs. 13.6%). Crude and adjusted hazard ratios from Cox proportional hazards 
model was shown in Table 5.12. Postdilation was associated with non-significantly lower risk of 
death/MI, repeat PCI/CABG, death/MI/CABG/thrombosis.  
5.5 DISCUSSION 
In this study we assessed whether postdilation is associated with either a beneficial effect or higher risk of 
cardiac adverse events after PCI procedure at one-year follow-up. Results showed minimal evidence of a 
protective effect among patients without AMI, while apparently no adverse effect associated with this 
strategy.  In contrast, our most compelling finding was an estimate 3-fold adjusted higher risk of death at 
1-year when postdilation is performed for a single lesion in the setting of acute MI.  However, this finding 
was not confirmed among acute MI patients with multiple lesions treated, leading to an equivocal 
interpretation as to the validity of the single lesion finding. 
The current stent delivery system uses semi-compliant balloon, which enables higher deployment 
pressure than previous delivery system using compliant balloon. However, only a few patients achieved 
optimum stent deployment. The POSTIT (Postdilation Clinical Comparative Study) trial found that only 
29% of patients achieved optimum stent deployment (defined as minimal stent diameter ≥ 90% average 
reference lumen diameter) through current bare metal stent (BMS) delivery system (Boston Scientific 
NIR, Guidant Tri-Star/Tetra, and Medtronic AVE S670 stents) [2]. Cheneau et al. reported that only 15% 
of patients achieved optimum stent deployment (defined as minimal stent cross-sectional area 
(CSA)/reference cross-sectional lumen area > 80%, or >90% if minimal lumen CSA < 9 mm2) with 
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current sirolimus-eluting stent (SES) delivery systems and an inflation pressure of 14 atm [3]. The most 
important reason for suboptimal stent expansion is balloon material. The delivery balloon in 
contemporary practice is semi-compliant, which are designed to maximize deliverability. As pressure 
inside the balloon increases, the balloon grows in the areas of less resistance. This results in stretching of 
the balloon around the lesion, instead of concentrating the force on the lesion. In contrast to semi-
compliant stent-delivery balloon, the balloon for postdilation is noncompliant, which change little in 
volume when inflation pressure increases. It delivers more focal force to the lesion. Deployment pressure 
is also associated with optimum stent deployment [1-3]. However, only 36% of patients achieved 
optimum stent deployment even at high deployment pressure of at least 14 atm [2].  
Previous studies showed that postdilation with noncompliant balloons can increase the frequency 
of optimum stent deployment. The POSTIT trial reported that after postdilation with noncompliant 
balloon minimal stent area (MSA) increased from 6.6 mm2 to 7.8 mm2, minimal stent diameter (MSD) 
increased form 2.6 mm to 2.8 mm and the optimum stent deployment rate doubled increased from 21% to 
42% [2]. The CRUISE (Can Routine Ultrasound Influence Stent Expansion) found that IVUS-guided 
group together with postdilation had larger MSA (7.8 vs. 7.1 mm2, p=0.001) and larger minimal lumen 
diameter (2.9 vs. 2.7 mm, p<0.001) when compared to standard angiography-guided group [13]. 
Johansson et al. reported 67% of patients got optimum stent deployment (MSA > 90% RLA) among a 
routine postdilation practice [14].  
MSA and stent underexpansion have been shown to be the two most important predictors of 
restenosis and target vessel revascularization (TVR) [15-20].  Although drug-eluting stent (DES) is 
effective in reducing the risk of TVR, it still occurs in 5% of patients following the procedure [21, 22]. 
Studies showed that postdilation with noncompliant balloon reduced the risk of target lesion 
revascularization (TLR) and TVR [13, 18, 23]. Stent thrombosis is another major concern for PCI 
procedure [24]. Its case-fatality rate is about 45% and nonfatal MI occurs in most of the survivors [25]. 
Studies showed that MSA and stent underexpansion are major predictors of stent thrombosis [25-27]. Up 
to today, there are little data about the relationship between postdilation and stent thrombosis. 
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Patients presenting with Acute MI usually have plaques that are more thrombotic and ulcerated 
than those seen in patients who present for PCI for indications other than Acute MI. Distal embolization 
of thrombotic debris may occur during and after PCI, happening more often when intervening in patients 
presenting with Acute MI, which leads to impaired microvascular perfusion, which in turn has been 
associated with MI, and mortality [4-6, 28-30]. We did observe an adverse effect of postdilation 
compared to no postdilation treatment among Acute MI patients who have only one lesion. The mortality 
risk among AMI patients receiving postdilation is 3.5 times that among AMI patient not receiving 
postdilation. The observed effect in our study is biologically plausible. However, we observed an opposite 
direction of postdilation effect among Acute MI patients who have more than one lesion, although none 
of these associations are statistically significant. This inconsistency of the postdilation effect among 
Acute MI patients can be the result of the poorly estimated effect due to the low sample size of Acute MI 
patients who with multiple lesions treated. However, it can also be a chance finding because the patients 
who did not receive postdilation had a very low event rate (1.7%, see Table 5.9), even lower than patients 
without AMI (4.7% for patients receiving no postdilation; 3.4% for patients receiving postdilation, see 
Table 5.3). Further study with larger sample size is required on this topic. 
There are limitations about our study. In our study, patients were not randomized to a strategy of 
postdilation versus no postdilation.  Therefore, we cannot exclude the possibility of residual confounding.  
With respect to the higher risk of death associated with postdilation among acute MI patients with a single 
lesion treated, it is possible that unobserved patient or procedural characteristics could explain, at least in 
part, the apparent difference in risk of death at 1-year. Though we considered an extensive array of factors 
that may have been associated with the decision of postdilation, it is still possible that one or more 
important variables were missed. A second limitation is the relatively small sample size among patients 
with multiple lesions treated, which leads to imprecise risk estimates. 
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5.6 CONCLUSIONS 
Among PCI patients presenting with Acute MI, postdilation may significantly increase the risk of death at 
1-year.  However, because this finding was observed only among patents with one lesion treated and not 
among patients with multiple lesions treated, the possibility of a chance finding exists.  Among PCI 
patients without AMI, lesion postdilation does not appear to be associated with either a benefit or 
increased risk of adverse cardiac events.  Further investigation is needed to determine whether a strategy 
of postdilation among acute MI patients should be discouraged.   
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Table 5.1 Patient demographics, disease history, and angiographic characteristics among patients 
without AMI who have one lesion treated 
 
Characteristics No postdilation    (n=1037) 
 Postdilation 
 (n=592) P value† P value‡ 
Female 31.9 33.5 0.53 0.98 
Age in years       64.5(11.3)           63.8(11.6) 0.23 0.84 
Race 
    White 
    Black 
    Asian 
    Other 
 
83.1 
13.2 
2.2 
1.5 
 
82.4 
13.9 
2.0 
1.7 
 
0.95 
 
0.65 
Hispanic 3.3 6.1   <0.01 0.97 
Insurance 
    Medicare 
    Other public 
    Private 
    None/self-pay 
 
36.6 
18.8 
43.8 
0.9 
 
31.8 
16.4 
49.8 
2.0 
 
0.02 
 
0.99 
Prior intervention 37.7 37.3 0.88 0.95 
Prior CABG 21.7 20.9 0.72 0.92 
Prior MI 27.1 27.6 0.83 0.86 
Severe non-cardiac disease 37.1 36.4 0.80 0.51 
History of diabetes 35.0 33.1 0.44 0.99 
History of chest pain 64.3 62.4 0.45 0.18 
Chest pain at admission 64.0 61.2 0.25 0.54 
History of CHF 11.6 8.2 0.03 0.84 
CHF at admission 5.3 5.1 0.84 0.66 
History of hypertension 81.6 78.3 0.11 0.81 
History of hypercholesterolemia 84.3 81.0 0.08 0.91 
Known hypercoagulable state 1.5 1.9 0.59 0.82 
Dominance 
    Left  
    Right 
    Balanced 
 
8.8 
81.7 
9.5 
 
7.9 
85.3 
6.7 
 
0.12 
 
0.99 
Amenable with CABG 71.1   78.4   <0.01 0.16 
Amenable with PCI 88.1 88.7 0.74 0.93 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention.  
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.2 Procedure and lesion characteristics among patients without AMI who have one lesion 
treated 
 
Characteristics No postdilation (n=1037) 
  Postdilation 
 (n=592) P value† P value‡ 
Cause of procedure 
    Unstable angina 
    Stable angina 
    Asymptomatic CAD 
    Others 
 
46.8 
29.9 
17.2 
6.2 
 
46.0 
29.7 
17.2 
7.1 
 
0.90 
 
0.99 
Procedure circumstance 
    Elective 
    Urgent 
    Emergent  
 
71.7 
27.7 
0.7 
 
73.1 
25.3 
1.5 
 
0.18 
 
0.99 
Procedure setting 73.3 79.4 <0.01 0.87 
Lesion length, mm        15.3(9.4)         19.1(12.8) <0.01 0.10 
Previously treated lesion 7.7 10.5 0.06 0.97 
Evidence of thrombus 5.6 7.9 0.06 0.97 
Calcification 25.8 38.0 <0.01 0.99 
Ulcerated 9.9 13.3 0.04 0.96 
Ostial lesion 8.1 10.0 0.20 0.96 
C type of ACC/AHA 
classification  
 
19.0 
 
31.9 
 
<0.01 
 
0.92 
CAD indicates coronary artery disease; ACC American College of Cardiology; AHA American Heart 
Association. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.3 One-year cumulative incident proportions and hazard ratios of adverse event among 
patients without AMI who have one lesion treated 
PCI indicates percutaneous coronary intervention; CABG coronary artery bypass graft surgery; MI 
myocardial infarction; MACE major adverse cardiac event; CI confidence interval. 
Event    N* 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 95% CI P value No postdilation (n=1037) 
 Postdilation
 (n=592) 
Death   47 4.7% 3.4% 0.78 0.81 0.41-1.59 0.54 
MI   49 3.2% 3.6% 1.22 1.27 0.68-2.36 0.45 
Repeat PCI 112 9.6% 7.9% 0.93 0.87 0.57-1.33 0.52 
CABG   19 1.1% 2.0% 1.99 2.23 0.84-5.96 0.11 
Repeat 
PCI/CABG 127 
     
10.6%      8.8% 0.99 0.95 0.64-1.41 0.80 
Death/MI   92 7.9% 6.0% 0.87 0.90 0.56-1.45 0.67 
Death/MI/CABG 107 8.8% 7.5% 0.95 0.97 0.63-1.50 0.89 
MACE    202   17.3%   13.5% 0.90 0.89 0.65-1.22 0.46 
 
* number of events 
† crude hazard ratio from Cox proportional hazards model 
‡ adjusted hazard ratio with propensity score in Cox proportional hazards model 
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Table 5.4 Patient demographics, disease history, and angiographic characteristics among patients 
without AMI who have more than one lesion treated 
 
Characteristics No postdilation 
(n=335) 
Postdilation 
(n=300) 
P value† P value‡ 
Female 33.0 31.6 0.70 0.99 
Age, y            66.3(11.3)           64.9(10.9) 0.11 0.77 
Race, % 
    White 
    Black 
    Asian 
    Other 
 
80.7 
14.3 
0.9 
4.2 
 
74.6 
17.6 
3.9 
3.9 
 
0.07 
 
0.99 
Hispanic 6.3 7.2 0.64 0.91 
Insurance 
    Medicare 
    Other public 
    Private 
    None/self-pay 
 
44.8 
14.9 
37.6 
3.3 
 
41.0 
15.6 
41.0 
2.3 
 
0.80 
 
0.78 
Prior intervention 35.7 32.6 0.40 0.87 
Prior CABG 23.5 16.3 0.02 0.98 
Prior MI 22.6 24.0 0.68 0.93 
Severe non-cardiac disease     
History of diabetes 36.0 38.8 0.47 0.74 
History of chest pain 60.8 59.4 0.73 0.84 
Chest pain at admission 60.2 60.6 0.92 0.91 
History of CHF 10.2 12.5 0.36 0.65 
CHF at admission 4.5 5.9 0.42 0.70 
History of hypertension 85.6 79.6 0.05 0.87 
History of hypercholesterolemia 79.8 81.5 0.59 0.68 
Known hypercoagulable state 1.7 4.4 0.10 0.86 
Dominance 
    Left  
    Right 
    Balanced 
 
11.6 
81.4 
7.0 
 
6.4 
84.9 
8.7 
 
0.07 
 
0.89 
Amenable with CABG 73.8 75.2 0.68 0.92 
Amenable with PCI 92.0 87.3 0.05 0.99 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention.  
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.5 Procedure and lesion characteristics among patients without AMI who have more than 
one lesion treated 
 
Characteristics No postdilation (n=335) 
Postdilation 
(n=300) P value† P value‡ 
Cause of procedure 
    Unstable angina 
    Stable angina 
    Asymptomatic CAD 
    Other 
 
47.6 
28.3 
17.0 
  7.1 
 
48.2 
28.3 
18.2 
  5.2 
 
0.67 
 
0.75 
Procedure circumstance 
    Elective 
    Urgent 
    Emergent  
 
74.3 
24.9 
  0.9 
 
73.6 
25.4 
  1.0 
 
0.98 
 
0.62 
Procedure setting 62.2 69.7 0.05 0.98 
Device access from femoral 95.5 94.5 0.53 0.14 
Number of lesions 
    2 
    3 
    4+ 
 
85.7 
12.2 
  2.1 
 
80.5 
15.6 
  3.9 
 
0.16 
 
0.99 
Total lesion, mm 29.2 33.6 0.23 0.96 
Lesion previously treated 95.8 96.4 0.70 0.99 
Evidence of thrombus   1.5   2.3 0.46 0.99 
Any calcification 25.9 30.9 0.16 0.96 
Any ulcerated   6.3   6.8 0.76 0.96 
Any ostial lesion   7.7   7.2 0.78 0.98 
Any C type ACC/AHA 
classification 
 
25.9 
 
31.6 
 
0.11 
 
0.99 
CAD indicates coronary artery disease; ACC American College of Cardiology; AHA American Heart 
Association. 
 
Categorical variables are presented as column percentages. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.6 One-year cumulative incident proportions and hazard ratios of adverse event among 
patients without AMI who have more than one lesion treated 
 
Event   N* 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 95% CI P value No postdilation (n=335) 
Postdilation 
(n=300) 
Death/MI 29   7.2%   5.0% 0.74 0.81 0.36-1.81 0.60 
Repeat PCI/CABG 64 12.0% 14.9% 1.31 1.39 0.82-2.38 0.22 
Death/MI/CABG/ 
repeat PCI 85 16.0% 20.0% 1.37 1.45 0.91-2.30 0.12 
MI indicates myocardial infarction; PCI percutaneous coronary intervention; CABG coronary artery 
bypass graft surgery. 
 
* number of events 
† crude hazard ratio without adjustment with propensity score.  
‡ Adjusted with propensity score as continuous variable. 
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Table 5.7 Patient demographics, disease history, and angiographic characteristics among Acute MI 
patients who have one lesion treated 
 
Characteristics No postdilation (n=445) 
Postdilation 
(n=268) P value† P value‡ 
Female 35.7 35.1 0.86 0.96 
Age in years          61.4(13.2)      62.2(12.4) 0.43 0.81 
Race 
   White 
   Black 
   Asian 
   Other 
 
77.1 
19.3 
2.9 
0.7 
 
78.7 
16.4 
3.0 
1.9 
 
0.43 
 
0.85 
Hispanic 3.2 7.5 0.01 0.96 
Insurance 
   Medicare 
   Other public 
   Private 
   None/self-pay 
 
30.4 
21.0 
42.8 
5.9 
 
35.6 
16.1 
42.3 
6.0 
 
0.33 
 
0.19 
Prior intervention 17.5 15.3 0.44 0.94 
Prior CABG 9.2 7.8 0.53 0.86 
Prior MI 16.1 15.8 0.91 0.95 
Severe non-cardiac disease 29.9 34.1 0.24 0.48 
History of diabetes 24.7 26.5 0.60 0.97 
History of chest pain 30.4 29.5 0.79 0.43 
Chest pain at admission 92.8 92.2 0.76 0.51 
History of CHF 5.1 7.6 0.18 0.99 
CHF at admission 10.3 7.5 0.20 0.96 
History of hypertension 67.5 69.3 0.62 0.94 
History of 
hypercholesterolemia 
 
65.7 
 
59.5 
 
0.11 
 
0.92 
Dominance 
   Left  
   Right 
   Balanced 
 
8.6 
80.4 
11.0 
 
4.8 
88.9 
6.3 
 
0.01 
 
0.99 
Amenable with CABG 74.2 78.4 0.21 0.42 
Amenable with PCI 92.1 90.7 0.50 0.95 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention.  
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.8 Procedure and lesion characteristics per patient among Acute MI patients who have one 
lesion treated 
 
Characteristics No postdilation (n=445) 
Postdilation 
(n=268) P value† P value‡ 
Procedure circumstance 
  Elective 
  Urgent 
  Emergent 
 
22.7 
38.0 
39.3 
 
20.9 
36.9 
42.2 
0.73 0.79 
Procedure site 86.3 89.2 0.26 0.96 
Total lesion,  mm           15.8(9.0)         20.4(11.8)      <0.01 0.77 
Previously treated lesion 3.8 4.1 0.85 0.83 
Evidence of thrombus 47.4 53.0 0.15 0.65 
Calcification 24.9 28.7 0.27 0.94 
Ulcerated 23.2 30.2 0.04 0.71 
Ostial lesion 4.0 8.2 0.02 0.93 
C type of ACC/AHA 
classification  
 
28.1 
 
36.9 
 
0.01 
 
0.67 
ACC indicates American College of Cardiology; AHA American Heart Association. 
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.9 One-year cumulative incident proportions and hazard ratios of adverse event among 
Acute MI patients who have one lesion treated 
PCI indicates percutaneous coronary intervention; CABG coronary artery bypass graft surgery; MI 
myocardial infarction; MACE major adverse cardiac event; CI confidence interval. 
Event   N* 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 95% CI P value No postdilation (n=445) 
Postdilation 
(n=268) 
Death 15 1.7% 4.5% 2.57 3.46 1.09-11.03 0.04 
MI 24 3.3% 5.0% 1.21 1.13 0.45-2.83 0.80 
Repeat PCI 47 6.9% 9.0% 1.25 1.41 0.73-2.71 0.30 
CABG 14 2.3% 3.0% 1.28 1.22 0.37-4.06 0.74 
Repeat 
PCI/CABG 60 
 
8.8% 
 
11.9% 
 
1.34 
 
1.49 
 
0.83-2.68 
 
0.18 
Death/MI 38 4.8% 9.5% 1.70 1.77 0.86-3.64 0.12 
Death/MI/CABG 49 6.9% 11.0% 1.51 1.48 0.79-2.81 0.22 
MACE 85 12.5% 18.2% 1.41 1.41 0.87-2.29 0.16 
 
* number of events 
† crude hazard ratio from Cox proportional hazards model 
‡ adjusted hazard ratio with propensity score in Cox proportional hazards model 
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Table 5.10 Patient demographics, disease history, and angiographic characteristics among Acute 
MI patients who have more than one lesion treated 
 
Characteristics No postdilation      (n=113) 
Postdilation 
   (n=112) P value† P value‡ 
Female 29.8 32.5 0.67 0.99 
Age       63.2(11.5)  62.9(13.7) 0.83 0.88 
White   82.5 77.2 0.32 0.97 
Insurance 
   Medicare 
   Other public 
   Private 
   None/self-pay 
 
33.3 
14.9 
48.3 
3.5 
 
36.9 
18.0 
35.1 
9.9 
 
0.11 
 
0.27 
Prior intervention 15.8 21.9 0.24 0.71 
Prior CABG 15.8 14.0 0.71 0.66 
Prior MI 17.3 30.4 0.02 0.92 
Severe non-cardiac disease 32.5 37.7 0.41 0.93 
History of diabetes 32.5 35.1 0.67 0.98 
History of chest pain 26.1 34.6 0.18 0.98 
Chest pain at admission 90.4 91.2 0.82 0.90 
History of CHF 7.4 9.0 0.67 0.75 
CHF at admission 10.8 7.1 0.33 0.91 
History of hypertension 75.0 71.7 0.57 0.53 
History of hypercholesterolemia 64.8 63.3 0.82 0.87 
Known hypercoagulable state 3.2 3.7 0.87 0.91 
Dominance 
    Left  
    Right 
    Balanced 
 
8.3 
79.8 
11.9 
 
6.1 
89.5 
4.4 
 
0.10 
 
0.99 
Amenable with CABG 77.2 80.7 0.52 0.79 
Amenable with PCI 86.8 92.1 0.20 0.94 
CABG indicates coronary artery bypass graft surgery; CHF congestive heart failure; MI myocardial 
infarction; PCI percutaneous coronary intervention.  
 
Categorical variables are presented as column percentages, continuous variables as mean±SD. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.11 Procedure and lesion characteristics among Acute MI patients who have more than one 
lesion treated 
 
Characteristics No postdilation (n=113) 
Postdilation 
(n=112) P value† P value‡ 
Procedure circumstance 
    Elective 
    Urgent 
    Emergent  
 
25.4 
48.3 
26.3 
 
23.7 
43.9 
32.5 
 
0.60 
 
0.89 
Procedure setting 79.0 88.6 0.05 0.90 
More than two lesions 13.2 21.1 0.12 0.90 
Any lesion >25mm 26.3 35.9 0.12 0.91 
Any lesion previously treated  98.3 99.1 0.57 0.97 
Any evidence of thrombus 14.9 10.5 0.32 0.67 
Any calcified lesion 28.1 28.1 1.00 0.93 
Any ulcerated lesion 12.3 14.0 0.70 0.57 
Any ostial lesion   4.4 9.7 0.13 0.99 
C type of ACC/AHA classification   29.0 30.7 0.77 0.74 
CAD indicates coronary artery disease; ACC American College of Cardiology; AHA American Heart 
Association. 
 
Categorical variables are presented as column percentages. 
† p value of tests for covariate balance between two treatments before propensity score adjustment 
‡ p value of tests for covariate balance between two treatments after propensity score adjustment 
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Table 5.12 One-year cumulative incident proportions and hazard ratios of adverse event among 
Acute MI patients who have more than one lesion treated 
 
Event N* 
Cumulative incident proportion Hazard 
Ratio† 
Hazard 
Ratio‡ 95% CI P value No postdilation(n=113) 
Postdilation 
(n=112) 
Death/MI 16   7.8%   9.2% 1.01 0.79 0.23-2.73 0.71 
Repeat PCI/CABG 24 13.6% 13.5% 1.12 0.99 0.36-2.73 0.98 
Death/MI/CABG/ 
repeat PCI 34 18.0% 20.9% 1.09 0.79 0.34-1.82 0.57 
PCI indicates percutaneous coronary intervention; CABG coronary artery bypass graft surgery; MI 
myocardial infarction; MACE major adverse cardiac event; CI confidence interval. 
 
* cumulative incident proportion 
† crude hazard ratio from Cox proportional hazards model 
‡ adjusted hazard ratio with propensity score in Cox proportional hazards model 
 
 98 
5.7 REFERENCES 
1. Nakamura, S., Hall, P., Gaglione, A., et al., High pressure assisted coronary stent implantation 
accomplished without intravascular ultrasound guidance and subsequent anticoagulation. Journal 
of the American College of Cardiology, 1997. 29(1): p. 21-7. 
 
2. Brodie, B.R., Cooper, C., Jones, M., et al., Is adjunctive balloon postdilatation necessary after 
coronary stent deployment? Final results from the POSTIT trial.(see comment]. Catheterization & 
Cardiovascular Interventions, 2003. 59(2): p. 184-92. 
 
3. Cheneau, E., Satler, L.F., Escolar, E., et al., Underexpansion of sirolimus-eluting stents: incidence 
and relationship to delivery pressure. Catheter Cardiovasc Interven, 2005(65): p. 222-226. 
 
4. Dibra, A., Mehilli, J., Dirschinger, J., et al., Thrombolysis in myocardial infarction myocardial 
perfusion grade in angiography correlates with myocardial salvage in patients with acute 
myocardial infarction treated with stenting or thrombolysis. Journal of the American College of 
Cardiology, 2003. 41(6): p. 925-9. 
 
5. Haager, P.K., Christott, P., Heussen, N., et al., Prediction of clinical outcome after mechanical 
revascularization in acute myocardial infarction by markers of myocardial reperfusion. Journal of 
the American College of Cardiology, 2003. 41(4): p. 532-8. 
 
6. Stone, G.W., Peterson, M.A., Lansky, A.J., et al., Impact of normalized myocardial perfusion 
after successful angioplasty in acute myocardial infarction. Journal of the American College of 
Cardiology, 2002. 39(4): p. 591-7. 
 
7. Rosenbaum, P.R. and Rubin, D.B., The central role of the propensity score in observational 
studies for causal effects. Biometrika, 1983(70): p. 41-55. 
 
8. Rosenbaum, P.R. and Rubin, D.B., Reducing bias in observational studies. J Am Stat Assoc, 
1984(79): p. 516-24. 
 
9. D'Agostino, R.B., Tutorial in biostatistics: propensity score methods for bias reduction in the 
comparison of a treatment to a non-randomized control group. Stat Med, 1998(17): p. 2265-81. 
10. Shah, B.R., Laupacis, A., Hux, J.E., et al., Propensity score methods gave similar results to 
traditional regression modeling in observational studies: a systematic review. Journal of Clinical 
Epidemiology, 2005. 58(6): p. 550-9. 
 
11. Sturmer, T., Joshi, M., Glynn, R.J., et al., A review of the application of propensity score methods 
yielded increasing use, advantages in specific settings, but not substantially different estimates 
compared with conventional multivariable methods. Journal of Clinical Epidemiology, 2006. 
59(5): p. 437-47. 
 
12. Stone, R.A., Obrosky, D.S., Singer, D.E., et al., Propensity score adjustment for pretreatment 
differences between hospitalized and ambulatory patients with community-acquired pneumonia. 
 99 
Pneumonia Patient Outcomes Research Team (PORT) Investigators. Medical Care, 1995. 33(4 
Suppl): p. AS56-66. 
 
13. Fitzgerald, P.J., Oshima, A., Hayase, M., et al., Final results of the Can Routine Ultrasound 
Influence Stent Expansion (CRUISE) study. Circulation, 2000. 102(5): p. 523-30. 
 
14. Johansson, B., Allared, M., Borgencrantz, B., et al., Standardized angiographically guided over-
dilatation of stents using high pressure technique optimize results without increasing risks. J 
Invasive Cardiolo, 2002(14): p. 227-229. 
 
15. Kasaoka, S., Tobis, J.M., Akiyama, T., et al., Angiographic and intravascular ultrasound 
predictors of in-stent restenosis. Journal of the American College of Cardiology, 1998. 32(6): p. 
1630-5. 
 
16. Hoffmann, R., Mintz, G.S., Mehran, R., et al., Intravascular ultrasound predictors of angiographic 
restenosis in lesions treated with Palmaz-Schatz stents. Journal of the American College of 
Cardiology, 1998. 31(1): p. 43-9. 
 
17. Sonoda, S., Morino, Y., Ako, J., et al., Impact of final stent dimensions on long-term results 
following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the 
sirius trial. Journal of the American College of Cardiology, 2004. 43(11): p. 1959-63. 
 
18. Takebayashi, H., Mintz, G.S., Carlier, S.G., et al., Nonuniform strut distribution correlates with 
more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation, 2004. 
110(22): p. 3430-4. 
 
19. Hong, M., Mintz, G.S., Lee, C.W., et al., Intravascular ultrasound predictors of angiographic 
restenosis after sirolimus-eluting stent implantation. Eur Heart J, 2006(27): p. 1305-1310. 
 
20. de Feyter, P.J., Kay, P., Disco, C., et al., Reference chart derived from post-stent-implantation 
intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary 
angiography. Circulation, 1999. 100(17): p. 1777-83. 
 
21. Moses, J.W., Leon, M.B., Popma, J.J., et al., Sirolimus-eluting stents versus standard stents in 
patients with stenosis in a native coronary artery.(see comment]. New England Journal of 
Medicine, 2003. 349(14): p. 1315-23. 
 
22. Stone, G.W., Ellis, S.G., Cox, D.A., et al., A polymer-based, paclitaxel-eluting stent in patients 
with coronary artery disease.(see comment]. New England Journal of Medicine, 2004. 350(3): p. 
221-31. 
 
23. Oemrawsingh, P.V., Mintz, G.S., Schalij, M.J., et al., Intravascular ultrasound guidance improves 
angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final 
results of a randomized comparison with angiographic guidance (TULIP Study). Circulation, 
2003. 107(1): p. 62-7. 
 
24. Cultp, D.E., Stent thrombosis: Historical perspectives and current trends. J Thromb  
Thrombolysis, 2000(10): p. 89-101. 
 
 100 
25. Iakovou, I., Schmidt, T., Bonizzoni, E., et al., Incidence, predictors, and outcome of thrombosis 
after successful implantation of drug-eluting stents.(see comment]. JAMA, 2005. 293(17): p. 
2126-30. 
 
26. Fujii, K., Carlier, S.G., Mintz, G.S., et al., Stent underexpansion and residual reference segment 
stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular 
ultrasound study. Journal of the American College of Cardiology, 2005. 45(7): p. 995-8. 
 
27. Downey, W., Brodie, B.R., Stuckey, T.D., et al., high risk of subacute stent thrombosis with 
long/multiple drug-eluting stents. Catheter Cardiovasc Interven, 2005(65): p. C-4. 
 
28. van 't Hof, A.W., Liem, A., Suryapranata, H., et al., Angiographic assessment of myocardial 
reperfusion in patients treated with primary angioplasty for acute myocardial infarction: 
myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation, 1998. 97(23): p. 
2302-6. 
 
29. Gibson, C.M., Cannon, C.P., Murphy, S.A., et al., Relationship of the TIMI myocardial perfusion 
grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes 
after thrombolytic administration in acute myocardial infarction. Circulation, 2002. 105(16): p. 
1909-13. 
 
30. Angeja, B.G., Gunda, M., Murphy, S.A., et al., TIMI myocardial perfusion grade and ST segment 
resolution: association with infarct size as assessed by single photon emission computed 
tomography imaging. Circulation, 2002. 105(3): p. 282-5. 
 
 101 
6.0  GENERAL DISCUSSION 
6.1 SUMMARY OF FINDINGS 
Although the guidelines for PCI procedures have been updated from the American College of Cardiology 
(ACC), American Heart Association (AHA), and the Society for Cardiovascular Angiography and 
Interventions (SCAI) periodically, the discretion from clinicians still plays an important role and thus 
results in significant variation in clinical practice of PCI. The objective of this dissertation research was to 
study the effect of the variation in three aspects on the patient outcomes, including post-discharge statin 
prescription, choice of stent number (multiple vs. single stent for each lesion), and postdilation. The 
results showed that this variation does have a strong impact on the risk of adverse patient outcomes. 
Specifically, in Research Paper 1 post-discharge statin treatment was associated with a 
significantly reduced risk of death, death/MI and death/MI/CABG, but not significantly associated with 
reduced risk of repeat PCI. In Research Paper 2, treatment with multiple stents per lesion was non-
significantly associated with higher risk of Repeat PCI/CABG, death/MI/CABG, death/MI/Thrombosis, 
death/MICABG/Thrombosis, but it was non-significantly associated with reduced risk of these adverse 
events among patients who have only one lesion treated  among patients who had more than one lesion 
treated,. In Research Paper 3, postdilation was significantly associated with dramatically increased risk of 
death and death/MI among acute MI patients who have one lesion treated, but this adverse effect was not 
seen among acute MI patients who have more than one lesion treated. Among patients without AMI, 
postdilation was not associated with either a benefit or increased risk of adverse cardiac events. 
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By use of propensity score methodology, our study controlled to a large extent for selection bias 
that can exist in observational studies.  Nonetheless, unobserved factors (residual confounding) may still 
have existed resulting in potentially biased estimates and impacting the validity of our conclusions. 
Technically, the randomized clinical trial with a large sample size can solve this potential problem. 
However, it would be very difficult to carry out, in practice, clinical trials for the 3 topics investigated in 
this dissertation. For the first topic, post-discharge statin was shown to be effective in our study, and its 
use among heart disease patients at large, including PCI patients, has been widely accepted (85% among 
PCI patients in our study). Thus, it may be both unethical and impractical to randomize patients into a 
placebo group. Patient adherence to treatment assignment may also be a problem. Furthermore, given 
practical and ethical constraints, we do not see an urgent need for a clinical trial to confirm the observed 
effect in our study since several large clinical trials have already proven its efficacy among other ischemic 
heart disease patients. For the second topic, multiple stents per lesion vs. single long stent per lesion, there 
is insufficient rationale for a clinical trial. Although there are no specific guidelines for the number of 
stents to treat each lesion, use of a single stent for lesions of 10-32 mm is  most common in contemporary 
practice (in our study, 88% of patients with single lesion treated received single stent and 81% of patients 
with more than one lesion treated received single stent for each lesion). The choice of multiple stents is 
the result of complex lesions, or unanticipated circumstances that occur during procedure, which requires 
additional stent for a full coverage. Even if enough patients could be recruited and randomized, it may be 
difficult to persuade clinicians to implant more than one stent if the disease and initial lesion result does 
not appear to warrant the use of more than one stent.  
Alternatively, a large carefully done observational study with data on why single or multiple 
stents were chosen could be helpful. For the third topic, we did observe a very strong adverse effect of 
postdilation among acute MI patients with one lesion treated. In our study, the risk of death in postdilation 
treatment was 3.5 times higher than in no postdilation treatment. Again, practical limitations indicate that 
it would be very difficult to randomize patients into a potentially hazardous practice without the perceive 
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equipoise of a possible beneficial effect.  Thus, on balance, the 3 topics investigated in this dissertation 
are likely to be adequately addressed within the framework of observational studies only. 
6.2 FUTURE RESEARCH 
Thrombosis is a rare event. However, the fatality rate is high. It is one major concern for PCI procedure, 
especially when drug-eluting stents greatly reduce the risk of restenosis. Because of low event numbers, 
we did not evaluate postdischarge statin, multiple stents vs. single long stent, or postdilation on the risk of 
thrombosis. In the future research, as the follow-up continues, and study population becomes larger, it is 
worthwhile to assess the effect of these variations on thrombosis specifically.  
For the same reason of small sample size, the effect estimates were not precise among the 
subgroup of patients who had more than one lesion treated. We do not expect dramatically different effect 
estimates between patients having one lesion treated and patients having more than one lesion treated. 
The inconsistent results in Paper 2 and Paper 3 among the two subgroups are very likely the results of 
small sample size of patients in the second subgroup: patients having more than one lesion treated. In 
future research the effect of these variations among the small subgroups needs to be reinvestigated to 
check consistency among the two subgroups. 
6.3 PUBLIC HEALTH SIGNIFICANCE 
According to the World Health Organization, cardiovascular disease (CVD) is the leading cause of 
mortality in nearly every region of the world, accounting for an estimated 30% of all deaths. Projections 
indicate that the proportion of cardiovascular deaths worldwide will increase from 29% in 1990 to 36% in 
2020. Coronary heart disease (CHD) is the principal type of heart disease. Worldwide, coronary heart 
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disease kills more than 7 million people each year. CHD death is about 71% of all heart disease deaths in 
2002 in US. Percutaneous coronary intervention (PCI) is the most common treatment for ischemic cardiac 
disease at contemporary practice. According to the American Heart Association, 70–90 percent of PCI 
procedures involve the implantation of a stent. About one million coronary artery stenting procedures are 
performed annually in the United States.  
Although guidelines are published and updated periodically from American College of 
Cardiology and American Heart Association and the Society for Cardiovascular Angiography and 
Interventions (SCAI), much variation exists in the practice of PCI procedure because the discretion of 
clinicians plays an important role on patient selection, stent type, number of stent, implantation procedure, 
et al. Our study showed the existence of these variations and assessed its impact on patient outcome at 
one-year follow up. It is of great public health significance to find the better practice for each specific 
type of patients in order to improves the patient outcome and thus improve the survival and quality of life 
for numerous patients suffering from this number-one killer disease.  
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APPENDIX A 
PROPENSITY SCORE MODELLING FOR PAPER ONE 
The list of baseline variables entered in the propensity score model, including demographic information: 
age (10-year increments), gender, race, ethnity, BMI (<25, 25-30, 30-35, 35-40, ≥40), enrollment time 
(wave 4/wave 5), disease history: history of coronary intervention, coronary bypass surgery, MI, severe 
concomitant non-cardiac disease (cerebrovascular, or PVD, or pulmonary disease, or cancer, or renal 
failure or other), diabetes, chest pain, chest pain at admission, congestive heart failure, congestive heart 
failure (CHF) at time of hospital admission, hypertension, hypercholesterolemia, known hypercoagulable 
state (history of hypercoagulability or excessive clotting as diagnosed by a physician or established by 
objective testing), angiographic characteristics: dominance (left, right, balanced), vessel disease (single, 
double or triple), evidence of minimal luminal irregularities in major vessels that are not significantly 
diseased (RCA, LAD, or LCx), the disease amenable to complete revascularization with CABG and 
percutaneous procedure according to the clinician, RCA ≥50% stenosis, any segment of RCA 100% 
stenosis, LAD ≥50% stenosis, any segment of LAD 100% stenosis, LCx ≥50% stenosis, any segment of 
LCx 100% stenosis, any bypass grafts, procedure characteristics: primary reason for revascularization 
(acute MI, unstable angina, stable angina, asymptomatic CAD, others), cardiogenic shock (yes/no), 
procedure circumstance (elective, urgent, emergent), device access site (femoral or not), renal-protective 
medication used (yes/no), IIb/IIIa receptor antagonist, Heparin, Clopidogrel, aspirin used < 24 hours prior 
to or during procedure (yes/no), procedure angiographically successful (all, partial success or failure), 
 106 
rotational atherectomy, other atherectomy attempt (yes/no), local drug delivery (yes/no),  patient being 
rejected for surgery (yes/no), lesion characteristics: number of lesions (one, two or more than two), any 
lesion length greater than 25 mm, number of narrow lesion less than 3 mm in diameter (none, one, more 
than one), any lesion previously treated, any evidence of thrombus, any calcified lesion, any ulcerated 
lesion, any lesion receiving collaterals, supplies collaterals, any ostial lesion, any tortuosity lesion, any C 
type lesion according to ACC/AHA classification, medication at discharge: beta blocker, ACE inhibitor, 
calcium channel blockers. 
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Table 6.1 Variables in logistic regression model to predict the conditional probability of receiving 
post-discharge statin 
 
Variable Variable label  β se P  
SEX gender Male vs. Female  -0.09 0.06 0.09 
age age <50 vs. ≥70 0.07 0.11 0.50 
  50-60 vs. ≥70 0.14 0.09 0.12 
  60-70 vs. ≥70 -0.05 0.09 0.54 
PPROC history of PCI Yes vs. No -0.12 0.06 0.04 
TYPRO Procedure circumstance Elective vs. Urgent -0.09 0.10 0.36 
  Emergent vs. Urgent -0.11 0.14 0.43 
primi history of MI Yes vs. No 0.17 0.07 0.02 
hxchf history of CHF Yes vs. No -0.26 0.08 0.00 
hxhyp histoty of hypertension Yes vs. No -0.19 0.07 0.01 
hxcho history of hypercholesterolemia Yes vs. No 0.48 0.06 <.0001 
hxcoa know hypercoagulable state Yes vs. No -0.47 0.17 0.01 
domin dominance Left vs. Right 0.20 0.11 0.07 
  Balanced vs. Right -0.14 0.20 0.49 
BMI BMI <25 vs. ≥40 -0.05 0.11 0.64 
  25-30 vs. ≥40 0.16 0.09 0.07 
  30-35 vs. ≥40 -0.01 0.10 0.93 
  35-40 vs. ≥40 0.15 0.15 0.31 
C type lesion 
C type according to AHA 
classification Yes vs. No -0.10 0.06 0.10 
length >25mm lesion length Yes vs. No 0.06 0.08 0.49 
EOT evidence of thrombus Yes vs. No 0.26 0.10 0.01 
CALC calcified Yes vs. No -0.06 0.06 0.29 
ULC ulcerated Yes vs. No -0.07 0.08 0.41 
BYPG bypass grafts Yes vs. No -0.11 0.09 0.19 
DATHN none evidence of minimal irregularity  Yes vs. No 0.04 0.06 0.48 
AMCAB amenable with CABG Yes vs. No -0.08 0.06 0.20 
AMPER amenable with PCI Yes vs. No 0.08 0.09 0.40 
number of lesions number of lesions treated 1 vs. ≥3 -0.38 0.14 0.01 
  2 vs. ≥3 -0.11 0.12 0.35 
RCA RCA 50% stenosis Yes vs. No 0.07 0.05 0.18 
rca100 RCA 100% stenosis No -0.09 0.07 0.23 
lad100 LAD 100% stenosis No 0.03 0.08 0.73 
acutemi acute MI No 0.14 0.09 0.15 
unstable unstable angina No 0.07 0.08 0.35 
stable stable angina No 0.14 0.08 0.09 
p_at other atherectomy attempt No 0.22 0.15 0.13 
p_drug local drug delivery No 0.22 0.17 0.19 
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Table 6.1 continued 
p_st stent attempt 1  vs. ≥3 0.21 0.11 0.05 
  2 vs. ≥3 -0.06 0.09 0.50 
DACE ACE inhibitors at discharge Yes vs. No 0.20 0.05 0.00 
DBB beta blockers at discharge Yes vs. No 0.18 0.08 0.02 
MDRA IIb/IIIa receptor antagonist Yes vs. No 0.21 0.06 0.00 
RENM renal-protective medication Yes vs. No -0.04 0.08 0.61 
pclop clopidogrel prior to procedure Yes vs. No 0.11 0.08 0.16 
diameter <3mm number of vessels whose 
diameter<3mm 
0 vs.  vs. ≥2 -0.10 0.09 0.30 
 1  vs. ≥2 -0.17 0.10 0.08 
se indicates standard error; P P value.  
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APPENDIX B 
PROPENSITY SCORE MODELLING FOR PAPER TWO 
A candidate list of baseline variables were entered in the propensity score model, including demographic 
information: age (10-year increment), gender, insurance and region; disease history: history of PCI, 
CABG, congestive heart failure, hypertension, hypercholesterolemia, diabetes, severe concomitant non-
cardiac disease (stroke, cancer, PVD, pulmonary, renal insufficiency, other);  procedure characteristics: 
primary indication for intervention, circumstances of procedure (elective, urgent, emergent), procedure 
sequence, MI type (ST elevation/Non ST elevation/Unknow), time from presentation of MI to 
intervention (≤12 hours/>12 hours), LV ejection fraction < 40%, use of rotational atherectomy, radiation 
therapy, and other interventional device;  and lesion characteristics: lesion length (measured in mm for 
patients with one lesion, measured as any lesion longer than 15 mm), any occlusion, any ostial lesion, any 
bifurcation, any calcification, any previously treated lesion, lesion attempted times, cutting balloon use, 
medication use before procedure: aspirin, Beta Blocker, GP IIb/IIIa inhibitor, Low-Molecular Weight 
Heparin, Statin, Direct Thrombin Inhibitor, Plavix and Ticlid. Medication use during procedure: aspirin, 
Beta Blocker, Planned GP IIb/IIIa inhibitor, Bail-out GP IIb/IIIa inhibitor, ACE inhibitors. 
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Table 6.2 Variables in logistic regression model to predict the conditional probability of receiving 
multiple stents (among patients with only one lesion treated) 
 
Variable Variable label  β se P  
age_cat age 55 to 64 vs. <55 0.07 0.12 0.55 
  65 to 74 vs. <55 -0.08 0.13 0.51 
  75 and older vs. <55 0.04 0.14 0.80 
GENDER gender Male vs. Female 0.04 0.08 0.65 
hxmi history of MI Yes vs. No 0.11 0.08 0.18 
hxhypertension history of hypertension Yes vs. No -0.07 0.09 0.44 
region_char region Midwest vs. West 0.12 0.14 0.39 
region_char  Northeast vs. West 0.23 0.13 0.07 
region_char  Southeast vs. West -0.45 0.16 0.00 
region_char  Southwest vs. West -0.05 0.25 0.83 
PROCSEQU procedure sequence staged vs. index 0.45 0.16 0.01 
calcification2 calcification Yes vs. No 0.11 0.08 0.16 
occlusion2 occlusion Yes vs. No 0.19 0.11 0.08 
bifurcation2 bifurcation Yes vs. No 0.17 0.12 0.16 
les_attempt lesion attempt two vs. one -0.33 0.40 0.41 
lcx LCx 50% stenosis Yes vs. No 0.10 0.08 0.22 
lcx_graft LCx graft Yes vs. No -0.24 0.25 0.35 
PRIMARYTX5 cutting balloon Yes vs. No 0.47 0.24 0.05 
PRIMARYTX7 other device Yes vs. No 0.20 0.18 0.27 
intraprocmeds2 beta blockers during procedure Yes vs. No 0.06 0.16 0.72 
preprocmeds2 beta blockers before procedure Yes vs. No -0.05 0.08 0.50 
preprocmeds3 IIb/IIIa receptor antagonist Yes vs. No 0.30 0.14 0.03 
preprocmeds6 Coumadin before procedrue Yes vs. No 0.15 0.22 0.49 
preprocmeds7 unfractured heparin before procedure Yes vs. No -0.18 0.11 0.09 
preprocmeds8 
low molecular weight heparin before 
procedure Yes vs. No -0.40 0.16 0.01 
preprocmeds9 statin before procedure Yes vs. No 0.08 0.08 0.32 
preprocmeds12 ACE inhibitors before procedure Yes vs. No 0.02 0.08 0.81 
preprocmeds13 no meds before procedure Yes vs. No 0.11 0.17 0.49 
LESLENGTH lesion length  -0.15 0.01 <.0001 
se indicates standard error; P P value.  
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 Table 6.3 Variables in logistic regression model to predict the conditional probability of receiving 
multiple stents (among patients with more than one lesion treated) 
 
Variable Variable label  β se P  
age_cat age 55 to 64 vs. <55 0.41 0.22 0.06 
  65 to 74 vs. <55 0.01 0.21 0.95 
  75 and older vs. <55 -0.04 0.24 0.88 
GENDER gender Male vs. Female -0.20 0.14 0.16 
pci_history prior PCI Yes vs. No -0.35 0.16 0.03 
hxmi history of MI Yes vs. No 0.24 0.15 0.12 
hxhypertension history of hypertension Yes vs. No -0.35 0.15 0.02 
diabetes_tx history of diabetes 1 vs. 0 -0.24 0.13 0.07 
indmitype1 MI type Yes vs. No -1.02 0.60 0.09 
indmitype2 MI timing Yes vs. No -0.98 0.52 0.06 
REVASCIND_r cause of procedure acute MI vs. others 1.37 0.79 0.08 
  
Unstables angina vs. 
others -0.44 0.29 0.12 
  stable angina vs. others -0.32 0.33 0.34 
  postive studyvs. others -0.70 0.32 0.03 
region_char region Midwest vs. West 0.12 0.25 0.63 
  Northeast vs. West 0.68 0.23 0.00 
  Southeast vs. West -0.37 0.27 0.17 
  Southwest vs. West -0.51 0.47 0.28 
PROCCIRCUM procedure circumstance Elective vs. Urgent 0.46 0.31 0.15 
  Emergent vs. Urgent -0.32 0.49 0.52 
lvef_lt40 LVEF<40% Yes vs. No -0.47 0.25 0.05 
calcification lesion calcification Yes vs. No 0.21 0.15 0.17 
lcx LCx 50% stenosis Yes vs. No 0.16 0.13 0.22 
intraprocmeds9 thrombin inhibitor Yes vs. No -0.10 0.13 0.45 
preprocmeds1 aspirin before procedure Yes vs. No -0.41 0.17 0.02 
preprocmeds8 
low molecular weight heparin 
before procedure Yes vs. No -0.42 0.29 0.15 
preprocmeds9 statin before procedure Yes vs. No -0.15 0.13 0.25 
number of 
lesions number of lesion treated  ≥3 vs. 2 0.24 0.18 0.17 
se indicates standard error; P P value.  
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APPENDIX C 
PROPENSITY SCORE MODELLING FOR PAPER THREE 
A list of candidate baseline variables entered to the propensity score model, including demographic 
information: age (10-year increments), gender, race, hispanic, insurance, BMI (<25, 25-30, 30-35, 35-40, 
≥40), enrollment time (Wave 4/Wave 5), disease history: history of coronary intervention, coronary 
bypass surgery, MI, severe concomitant non-cardiac disease (cerebrovascular, or peripheral vascular 
disease, or pulmonary disease, or cancer, or renal failure or other), diabetes, chest pain, chest pain at 
admission, congestive heart failure, congestive heart failure at time of hospital admission, hypertension, 
hypercholesterolemia, known hypercoagulable state (history of hypercoagulability or excessive clotting as 
diagnosed by a physician or established by objective testing), angiographic characteristics: dominance 
(left, right, balanced), vessel disease (single, double or triple), RCA, LAD, or LCx 50% stenosis, the 
disease amenable to complete revascularization with CABG according to the clinician, the disease 
amenable to complete revascularization with percutaneous procedure according to the clinician, any 
bypass grafts, procedure characteristics: cause of procedure (acute MI, unstable angina, stable angina, 
asymptomatic CAD, others), procedure site (same as diagnostic site), cardiogenic shock (yes/no),  
procedure circumstance (elective, urgent, emergent), procedure site (same to diagnostic site: yes/no), 
device access site (femoral or not), rotational atherectomy, other atherectomy, cutting balloon, 
thrombolytics reperfusion, any drug-eluting stent, renal-protective medication used (yes/no), medication 
used < 24 hours prior to procedure (IIb/IIIa receptor antagonist, Heparin, Clopidogrel, aspirin: yes/no), 
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local drug delivery (yes/no), patient being rejected for surgery (yes/no), lesion characteristics: number of 
lesions (one, two or more than two), any lesion length greater than 25 mm, any lesion previously treated, 
any evidence of thrombus, any calcified lesion, any ulcerated lesion, any lesion receiving collaterals, 
supplies collaterals, any ostial lesion, any tortuosity lesion, any C type lesion according to ACC/AHA 
classification. For patients with one lesion treated, the lesion length (<10mm, 10-15mm, 15-20mm, 
≥20mm), vessel diameter (<2.5mm, 2.5-3.0mm, 3.0-3.5mm, ≥3.5mm), stent diameter bigger than vessel 
diameter (yes/no), number of stent (1, 2, 3 or more). 
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Table 6.4 Variables in logistic regression model to predict the conditional probability of receiving 
postdilation (among patients without AMI and had only one lesion treated) 
 
Variable Variable label  β se P  
SEX gender  Male vs. Female 0.07 0.06 0.27 
HISPA hispanic Yes vs. No -0.35 0.13 0.01 
TYPRO procedure circumstance Elective vs. urgent 0.20 0.20 0.33 
  Emergent vs. urgent -0.53 0.38 0.16 
HXDB history of diabetes Yes vs. No 0.05 0.06 0.38 
hxchf history of CHF Yes vs. No 0.13 0.10 0.19 
hxhyp history of hypertension Yes vs. No 0.07 0.07 0.32 
hxcho history of hypercholesterolemia Yes vs. No 0.15 0.08 0.05 
vdiscal vessel disease Triple vs. non triple -0.15 0.08 0.06 
dominance dominance left vs. right -0.13 0.11 0.23 
  balanced vs. right -0.15 0.11 0.17 
SAMEP 
procedure site same as 
diagnostic site Yes vs. No -0.22 0.07 0.00 
rca RCA 50% stenosis Yes vs. No -0.16 0.13 0.22 
lad LAD 50% stenosis Yes vs. No -0.11 0.12 0.35 
lcx LCx 50% stenosis Yes vs. No -0.16 0.13 0.21 
rcaocl RCA 100% stenosis Yes vs. No 0.09 0.09 0.31 
ladocl LAD 100% stenosis Yes vs. No -0.10 0.09 0.26 
lcxocl LCx 100% stenosis Yes vs. No 0.12 0.09 0.22 
wave enrollment time wave 4 vs. wave 5 0.06 0.06 0.34 
lptt previously treated Yes vs. No -0.18 0.10 0.07 
HEPP heparin prior to procedure Yes vs. No 0.27 0.14 0.05 
EOT evidence of thrombus Yes vs. No -0.11 0.12 0.33 
CALC calcified Yes vs. No -0.25 0.06 0.00 
OLES ostial lesion Yes vs. No -0.13 0.10 0.21 
TORT lesion tortuosity Moderate/Severe vs. none 0.13 0.07 0.06 
p_drug local drug delivery Yes vs. No 0.38 0.21 0.07 
p_ra rotational atherectomy Yes vs. No 0.31 0.24 0.20 
p_at other atherectomy attempt Yes vs. No 0.35 0.18 0.05 
rrev2 cause of procedure  Unstable vs. other -0.01 0.11 0.89 
  Stable vs. other 0.06 0.11 0.57 
  Asymptomacit CAD vs. other 0.20 0.12 0.10 
Age age >40 vs. ≥80 0.44 0.41 0.28 
  40-50 vs. ≥80 -0.27 0.18 0.13 
  50-60 vs. ≥80 0.00 0.14 0.99 
  60-70 vs. ≥80 -0.01 0.13 0.95 
  70-80 vs. ≥80 -0.07 0.14 0.61 
ov_elut_le overall drug-eluting stents use Yes vs. No -0.14 0.09 0.12 
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Table 6.4 continued 
acc4 C type lesion according to AHA Yes vs. No -0.25 0.07 0.00 
number of 
stents number of stents 1 vs ≥3 -0.02 0.11 0.86 
  2 vs. ≥3 -0.32 0.12 0.01 
pasp aspirin prior to procedure Yes vs. No -0.18 0.11 0.10 
ptic 
clopidogrel or ticlopidine prior 
to procedure Yes vs. No 0.36 0.37 0.33 
DASP aspirin at discharge Yes vs. No 0.32 0.18 0.07 
dclotic 
clopidogrel or ticlopidine at 
discharge Yes vs. No 0.24 0.19 0.20 
DLAN long acting nitrates at discharge Yes vs. No 0.09 0.08 0.28 
DACE ACE inhibitors at discharge Yes vs. No -0.06 0.06 0.27 
dcstcost cholesterol modifying agents Yes vs. No 0.13 0.08 0.14 
DATHN 
none luminal irregularities in 
major vessel Yes vs. No -0.20 0.09 0.02 
DATHR RCA minimal irregularities Yes vs. No -0.05 0.07 0.45 
DATHC LCx minimal irregularities Yes vs. No -0.14 0.07 0.04 
norm vessel diameter >2.5 vs. ≥3.5 -0.10 0.18 0.60 
  2.5-3.0 vs. ≥3.5 0.27 0.11 0.01 
  3.0-3.5 vs. ≥3.5 -0.07 0.10 0.50 
stvessel 
stent diameter bigger than vessel 
diameter big stent vs. smaller stent 0.45 0.07 <.0001 
len lesion length 0-10 vs. ≥20 0.03 0.21 0.87 
  10-15 vs. ≥20 -0.22 0.19 0.24 
  15-20 vs. ≥20 -0.57 0.20 0.00 
PAY insurance Medicare vs. Private 0.53 0.16 0.00 
  None/self-pay vs. Private -0.75 0.38 0.05 
  Other public vs. Private 0.13 0.17 0.46 
se indicates standard error; P P value.  
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Table 6.5 Variables in logistic regression model to predict the conditional probability of receiving 
postdilation (among patients without AMI and had multiple lesions treated) 
 
Variable Variable label  β se P  
SEX gender Male vs. Female -0.05 0.10 0.61 
RACE race Asian vs. White 1.34 0.55 0.01 
  Black vs. White -0.06 0.28 0.84 
  Other vs. White -0.91 0.43 0.03 
PRIBY prior PCI Yes vs. No -0.52 0.16 0.00 
primi history of MI Yes vs. No 0.02 0.11 0.88 
hxcp history of chest pain Yes vs. No -0.07 0.10 0.51 
cpain chest pain at admission Yes vs. No -0.09 0.12 0.46 
hxhyp history of hypertension Yes vs. No -0.20 0.12 0.11 
hxcho history of hypercholesterol Yes vs. No 0.10 0.12 0.37 
hxcoa 
known hypercoagulable 
state Yes vs. No 0.69 0.37 0.07 
smoke smoking current smoker vs. others -0.21 0.14 0.12 
  
former smokers vs. 
others -0.15 0.10 0.16 
SAMEP 
procedure site same as 
diagnostic site Yes vs. No 0.22 0.10 0.03 
domin dominance left vs. other 0.45 0.18 0.01 
vdiscal3 vessel disease triple vs. others 0.38 0.17 0.03 
len2 any lesion length >25mm 
longer than 25 mm  vs. 
not  0.09 0.10 0.39 
LPT2 any lesion previously treated Yes vs. No -0.01 0.25 0.98 
EOT2 
any lesion had evidence of 
thrombus Yes vs. No 0.44 0.34 0.19 
CALC2 any lesion calcified Yes vs. No 0.06 0.10 0.55 
ULC2 any lesion ulcerated Yes vs. No 0.09 0.19 0.65 
OLES2 any ostial lesion Yes vs. No 0.11 0.18 0.54 
C lesion any C type lesion  Yes vs. No 0.19 0.11 0.08 
Age age <50 vs. >70 0.17 0.20 0.41 
  50-60 vs. >70 -0.11 0.16 0.48 
  60-70 vs. >70 0.13 0.15 0.41 
DATHN 
no minimal irregularities in 
major vessel Yes vs. No 0.47 0.14 0.00 
DATHR RCA minimal irregularities Yes vs. No 0.26 0.12 0.02 
DATHC LCx minimal irregularities Yes vs. No 0.26 0.12 0.03 
AMPER amenable with PCI Yes vs. No 0.39 0.16 0.02 
cnt numer of lesion treated 2 vs. ≥4 -0.19 0.24 0.44 
  3 vs. ≥4 0.14 0.27 0.61 
RCA RCA 50% stenosis Yes vs. No 0.41 0.16 0.01 
LAD LAD 50% stenosis Yes vs. No 0.57 0.16 0.00 
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Table 6.5 continued 
LCX LCx 50% stenosis Yes vs. No 0.34 0.13 0.01 
rca100 RCA 100% stenosis Yes vs. No -0.24 0.15 0.12 
lad100 LAD 100% stenosis Yes vs. No 0.31 0.16 0.05 
unstable unstable angina Yes vs. No 0.21 0.22 0.34 
stable stable angina Yes vs. No 0.20 0.22 0.36 
asymcad asymptomatic CAD Yes vs. No 0.13 0.22 0.54 
p_drug local drug delivery Yes vs. No -0.41 0.29 0.16 
p_ra 
rotational atherectomy 
attempt Yes vs. No 0.22 0.27 0.40 
p_st stent attempt 2 vs. ≥3 -0.35 0.21 0.10 
DBB beta blockers at discharge Yes vs. No -0.13 0.11 0.23 
DCAL 
calcium channel blockers at 
discharge Yes vs. No 0.08 0.12 0.51 
p_nd new device attempted 2 vs. ≥3 0.33 0.20 0.10 
MDRA IIb/IIIa receptor antagonist Yes vs. No 0.14 0.11 0.22 
RENM renal protective medicine Yes vs. No -0.30 0.16 0.06 
phep heparin prior to procedure Yes vs. No -0.16 0.10 0.10 
pasp aspirin prior to procedure Yes vs. No -0.08 0.15 0.59 
norm vessel diameter< 3mm Yes vs. No 0.06 0.09 0.53 
se indicates standard error; P P value.  
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Table 6.6 Variables in logistic regression model to predict the conditional probability of receiving 
postdilation (among patients with AMI and had only one lesion treated) 
 
Variable Variable label  β se P  
SEX gender Male vs. Female -0.04 0.10 0.67 
HISPA hispanic Yes vs. No -0.38 0.21 0.07 
BMI BMI <25 vs. ≥39 -0.06 0.19 0.74 
  25-30 vs. ≥39 -0.31 0.17 0.07 
  30-35 vs. ≥39 0.06 0.19 0.75 
  35-39 vs. ≥39 -0.16 0.27 0.56 
PPROC prior PCI Yes vs. No 0.13 0.15 0.40 
PRIBY prior CABG Yes vs. No -0.22 0.22 0.33 
primii history of MI Yes vs. No -0.17 0.16 0.28 
HXDB history of diabetes Yes vs. No -0.17 0.11 0.11 
hxchff histroy of CHF Yes vs. No -0.52 0.21 0.01 
hxhypp history of hypertension Yes vs. No -0.20 0.11 0.07 
HACHF CHF at admission Yes vs. No 0.50 0.18 0.01 
hxchoo history of hypercholesterolemia Yes vs. No 0.21 0.10 0.04 
dominance dominance left vs. right -0.45 0.19 0.02 
  balanced vs. right -0.39 0.17 0.02 
vdiscal2 vessel disease Yes vs. No -0.16 0.10 0.11 
SAMEP 
procedure site same as 
diagnostic site Yes vs. No -0.12 0.14 0.40 
rca RCA 50% stenosis Yes vs. No -0.54 0.30 0.07 
lad LAD 50% stenosis Yes vs. No -0.82 0.29 0.01 
lcx LCx 50% stenosis Yes vs. No -0.77 0.30 0.01 
ladocl LAD 100% stenosis Yes vs. No 0.22 0.13 0.11 
lcxocl LCx 100% stenosis Yes vs. No 0.31 0.15 0.04 
AMPER amenable with PCI Yes vs. No -0.33 0.17 0.05 
wave enrollment time wave 4 vs. wave 5 0.16 0.10 0.08 
HEPP heparin prior to procedure Yes vs. No -0.17 0.11 0.13 
RCOL receive collaterals Yes vs. No -0.50 0.13 <.0001 
OLES ostial lesion Yes vs. No -0.39 0.20 0.05 
TORT lesion tortuosity 
Moderate/Severe vs. 
none 0.10 0.11 0.39 
p_drug local drug delivery Yes vs. No 0.26 0.19 0.16 
p_at othe atherectomy attempt Yes vs. No 0.61 0.59 0.30 
Age age >40 vs. ≥80 0.64 0.48 0.19 
  40-50 vs. ≥80 -0.08 0.22 0.71 
  50-60 vs. ≥80 -0.02 0.19 0.92 
  60-70 vs. ≥80 0.00 0.20 0.99 
  70-80 vs. ≥80 -0.27 0.21 0.21 
SHOCK shock Yes vs. No 0.14 0.26 0.59 
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Table 6.6 continued 
number of 
stents number of stents 1 vs ≥3 0.25 0.18 0.17 
  2 vs. ≥3 -0.19 0.20 0.34 
len lesion length 0-10 vs. ≥20 0.07 0.27 0.80 
  10-15 vs. ≥20 0.32 0.24 0.18 
  15-20 vs. ≥20 -0.34 0.24 0.15 
stvessel 
stent diameter bigger than vessle 
diameter 
big stent vs. smaller 
stent 0.51 0.10 <.0001 
pasp aspirin prior to procedure Yes vs. No 0.10 0.15 0.48 
DLAN long acting nitrate at discharge Yes vs. No 0.25 0.21 0.22 
DBB beta blockers at discharge Yes vs. No 0.22 0.15 0.14 
dcstcost cholesterol modifying agents Yes vs. No -0.06 0.15 0.70 
se indicates standard error; P P value.  
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 Table 6.7 Variables in logistic regression model to predict the conditional probability of receiving 
postdilation (among patients with AMI and had more than one lesion treated) 
 
Variable Variable label  β se P  
SEX gender Male vs. Female 0.12 0.23 0.61 
HISPA hispanic Yes vs. No 0.43 0.47 0.36 
RACE race White vs. Non white -0.26 0.26 0.32 
primii history of MI Yes vs. No 0.67 0.25 0.01 
codiss severe non cardiac events Yes vs. No 0.46 0.23 0.04 
HXDB history of diabetes Yes vs. No 0.33 0.21 0.12 
hachff history of CHF Yes vs. No -0.34 0.36 0.35 
hxchoo history of hypercholesterolemia Yes vs. No -0.25 0.21 0.24 
smoke2 smoking Yes vs. No 0.35 0.21 0.09 
SHOCK shock  Yes vs. No 1.42 0.87 0.10 
SAMEP procedure site same as diagnostic site Yes vs. No 0.26 0.28 0.37 
domin dominance left vs. right 0.46 0.37 0.21 
  balanced vs. right 0.57 0.35 0.11 
vdis vessel disease double vs. other -0.29 0.21 0.16 
BMI BMI <25 vs. >=40 0.61 0.44 0.17 
  25-30 vs. >=40 0.24 0.38 0.53 
  30-35 vs. >=40 0.69 0.39 0.08 
  35-40 vs. >=40 0.43 0.64 0.50 
len2 any lesion length >25mm Yes vs. No 0.32 0.23 0.16 
LPT2 any lesion previously treated Yes vs. No 0.96 0.82 0.24 
CALC2 any lesion calcified Yes vs. No -0.18 0.23 0.43 
OLES2 anly ostial lesion Yes vs. No 0.82 0.40 0.04 
Age age <50 vs. >70 0.24 0.40 0.55 
  50-60 vs. >70 0.10 0.36 0.79 
  60-70 vs. >70 -0.05 0.33 0.88 
DATHC LCx minimal irregularities Yes vs. No 0.26 0.20 0.20 
AMPER amenable with PCI Yes vs. No -0.47 0.34 0.17 
CABGR rejected for CABG Yes vs. No -0.68 0.54 0.21 
number 
of lesions number of lesion 2 vs. ≥3 0.10 0.32 0.75 
RCA RCA 50% stenosis Yes vs. No 0.22 0.26 0.39 
LAD LAD 50% stenosis Yes vs. No 0.36 0.25 0.14 
rca100 RCA 100% stenosis Yes vs. No -0.39 0.25 0.12 
p_st stent attempt 2 vs. ≥3 -1.22 0.52 0.02 
DBB beta blockers at discharge Yes vs. No 0.56 0.32 0.08 
p_nd new device attemptd 2 vs. ≥3 0.82 0.52 0.12 
MPRA IIb/IIIa receptor antagonist Yes vs. No -0.80 0.25 0.00 
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Table 6.7 continued 
RENM renal protective medicine Yes vs. No 0.56 0.28 0.04 
RTHR thrombolytic reperfusion Yes vs. No 1.78 0.70 0.01 
pasp aspirin prior to procedure Yes vs. No -0.84 0.32 0.01 
norm  vessel diameter <3 mm Yes vs. No 0.38 0.21 0.07 
se indicates standard error; P P value.  
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